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Abstract
Chronic kidney disease (CKD) affects 10% of the population in industrialized nations.
Recent genome wide association studies (GWAS) have correlated SHROOM3 with
glomerular filtration rate and albuminuria. To elucidate Shroom3’s role in the kidney, I
employed a gene trap mouse model (Shroom3Gt/Gt allele) that produces a non-functional
Shroom3 protein. Shroom3 is expressed in the podocytes embryonically and in adulthood as
well as other cell types. Shroom3 loss results in glomerular cysts and reduced glomerular
number. Some Shroom3+/Gt and Shroom3Gt/Gt podocytes showed loss of apical ROCK1,
pMLC and actin consistent with the role of Shroom3 in actin organization. Shroom3+/Gt also
showed reduced glomerular number and cystic glomeruli and some adult Shroom3+/Gt have
albuminuria, a sign of CKD. Therefore, Shroom3 is required for normal kidney development
and reduced Shroom3 function can result in adult-onset kidney disease. This provides a
mechanistic explanation for the GWAS studies in humans correlating SHROOM3 with CKD.

Keywords
Shroom3, nephrogenesis, kidney, chronic kidney disease, actin, cytoskeleton, podocyte,
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Chapter 1

1

Introduction

Chronic kidney disease (CKD) is characterized by progressive loss of kidney function
resulting in the need for dialysis or kidney transplant for survival. The kidneys are
essential for a number of functions, one of which is to filter the blood and regulate excess
electrolytes and remove wastes in the urine while maintaining vital serum substances
including cells and high molecular weight proteins. CKD is a significant cause of
morbidity and mortality in industrialized nations affecting about 10% of the population
(Coresh et al., 2007; Hallan et al., 2006; Zhang & Rothenbacher, 2008). One gold
standard method to determine whether a patient suffers from CKD is estimation of
glomerular filtration rate (GFR). If GFR is <60 mL/min/1.73m2, the patient is deemed to
have CKD (National Kidney Foundation, 2002). A normal GFR is approximately 120
mL/min/1.73m2. An important factor in GFR is podocyte health. Podocytes are cells that
form an integral part of the filtration barrier as their foot processes wrap around the
capillaries of the glomerulus with a protein bridge, the slit diaphragm, connecting
neighbouring foot processes. These foot processes prevent large molecular weight
proteins and cells from being filtered into the urine. Foot processes are maintained by the
actin cytoskeleton. Perturbations in the functioning of the podocyte actin cytoskeleton
can result in disruption of the podocyte foot processes and thus the filtration barrier
leading to kidney disease with consequences such as proteinuria.
A number of different genome-wide association studies (GWAS) have correlated genetic
regulators to kidney function and disease. SHROOM3 has been identified as a candidate
for being one of those genetic regulators. Shroom3 is an actin-binding protein that is
known to drive specific cell shape changes and subsequent tissue morphogenesis.
Because the actin cytoskeleton is so important to podocyte foot process morphology and
function, it suggests a possible scenario where Shroom3, an actin binding and actin
regulating protein, plays a vital role in podocyte foot process development and variants in
SHROOM3 might increase susceptibility to CKD. If this scenario is verified, SHROOM3
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sequencing may be useful therapeutic information in the early diagnosis, treatment and
prevention of CKD.

1.1 Mouse Kidney
1.1.1

Development of the Kidney

The kidneys are bilateral organs that have a number of important functions in the body
(Davidson, 2009). The basic function of the kidney is to remove waste products and
regulate water and electrolyte levels in the blood while maintaining essential compounds
in the body. To remove substances from the body, the kidney concentrates the waste
products and excretes them in the form of urine. Since the kidney has important excretory
functions, the kidneys also function to regulate blood pH, water levels, electrolyte
concentrations, removal of foreign substances such as drugs, and long-term regulation of
blood pressure.
The mammalian kidney progresses through three stages of development: the pronephros,
mesonephros, and metanephros (Davidson, 2009). The pronephros and mesonephros are
transient structures in mammals with little to no functional ability. In mammals, the
metanephros persists as the adult kidney structure. However, in lower vertebrates, such as
zebrafish and Xenopus, the persistent adult kidney is the mesonephros and not the
metanephros (Wessely & Tran, 2011). Furthermore, in aquatic animals such as Xenopus,
the pronephros is fully functional in order to regulate water balance in their aquatic
environment.
In mice, metanephros development is initiated at embryonic day (E) 10.5 when there is an
outgrowth of the nephric duct known as the ureteric bud (Davidson, 2009). The ureteric
bud invades into the surrounding metanephric mesenchyme, or cap mesenchyme.
Interactions between the mesenchyme and nephric bud cause the bud to undergo
approximately 11 cycles of branching, eventually becoming the collecting duct system.
At each tip of the ureteric bud, a nephron will develop. Nephrons are the functional unit
of the kidney and consist of the glomerulus, Bowman’s capsule, and tubules (Figure 1).
The most proximal portion of the nephron is the glomerulus. The glomerulus is involved
in the filtration of the blood to remove waste and excess substances while the tubules are
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involved in reabsorption and secretion. The tubules are vital in fine-tuning of the filtrate
from the glomerulus before elimination in the urine. The nephron itself develops from
progenitors in the cap mesenchyme, rather than the ureteric bud that proliferate and
differentiate into glomerular and tubular epithelial cells.
The metanephric nephron goes through several morphological stages before reaching full
maturity (Davidson, 2009). Initially there is a pretubular aggregate, which develops into a
renal vesicle (Figure 2). Following the renal vesicle, morphogenesis of this epithelium
forms a comma-shaped body, then an S-shaped body. Lastly, there is maturation of the
glomerulus and fusion of the tubule with the collecting duct system. The maturation of
the glomerulus involves the development of the capillary system. A mature glomerular
capillary system contains six to eight loops (Figure 3) (Potter, 1965). In mouse, unlike
humans where kidney development is finished by the time of birth, nephrogenesis
continues for two weeks postnatally (Davidson et al., 2009; Rocque et al., 2015).
Moreover, humans have large variability in the number of nephrons per kidney, ranging
from approximately 200,000 to 1,800,000 nephrons per kidney (Hoy et al., 2003;
Hughson et al., 2003; Nyengaard & Bendtsen, 1992). Mice, on the other hand, have less
variability and only have about 13,000 nephrons per kidney (Rocque & Torban, 2015).
Due to the smaller “normal” range of nephrons in mice, it is easier to determine if certain
genes play a direct role in determining nephron endowment. Thus, mice are an excellent
model for looking at kidney defects and potential genetic regulators of nephrogenesis.

4

Mouse kidney development

Figure 1. Structure of the mammalian kidney. Each kidney is comprised of a fibrous outer layer called the renal capsule, a peripheral layer called the
cortex, and an inner layer called the medulla. The medulla is arranged in multiple pyramidal structures that together with overlying cortex comprise a renal
lobe (red box). Urine drains from the tip of each pyramid (papilla) into minor and major calices that empty into the renal pelvis. The renal pelvis then transmits
the urine to the bladder via the ureter. Nephrons are found within the cortex and medulla and have a characteristic structure that includes a glomerular
blood filter containing podocytes and a tubular epithelium that loops down into the medulla. The tubule is subdivided into proximal, intermediate, and distal
segments (see color key) that are important for the recovery and modification of the glomerular filtrate.

Figure 1. Structural diagram of the mammalian kidney. The gross anatomical

structure of a kidney is shown on the left. A schematic of the different parts of the

nephron
Abstract

is found on the right. The nephron is the functional unit of the kidney and is
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contribute to the formation of the glomerulus (Eremina et al., 2003). As proliferation of the nascent
s, the proximal and distal tubule segments become convoluted while the region between them grows
dullary zone to form the Loop of Henle (Neiss, 1982). Nephrons located in superficial or midcortical
dney possess short loops of Henle that turn within the cortex or outer medulla zone. More deeply
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mechanisms of metanephric nephron formation

ting experiments identified Wnt9b and Wnt4 as being necessary for pre-tubular aggregate formation
formation, respectively (Carroll et al., 2005; Kispert et al., 1998; Stark et al., 1994). Wnt9b is expressed
B-derived collecting duct system (excluding the UB tips) and is considered the primary UB-derived
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he widespread expression pattern of Wnt9b throughout the collecting system only a small subset of
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n of pre-tubular aggregates on the distal side of the UB tip (Kobayashi et al., 2008; Self et al., 2006).
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1.1.2

Podocyte Biology

Podocytes are specialized epithelial cells that wrap around the capillaries of the
glomerulus and sit on top of the glomerular basement membrane (GBM) (Faul et al.,
2007). Podocytes appear during the S-shaped body phase of glomerular development
(Kreidberg et al., 2003). During the transition from an S-shaped body to a mature
glomerulus, the podocytes become distinct from the other cells of the nephron and
express podocyte-specific markers within the kidney such as WT1 and nephrin (Figure 3)
(Armstrong et al., 1993; Kestilä et al., 1998; Putaala et al., 2000). Podocytes are
terminally differentiated and as such, are thought to be incapable of proliferation.
Therefore when injured, the damage is irreversible and cell death will reduce podocyte
number (Mouawad et al., 2013).
The basal portion of podocytes rests on the GBM while the apical surface faces the
Bowman’s capsule (Kreidberg et al., 2003). Podocytes contain three segments: the cell
body, primary processes (or major processes) and secondary processes known as foot
processes (Figure 4) (Faul et al., 2007). The major processes connect the cell body with
the foot processes that contain an actin cytoskeleton. The actin cytoskeleton of the foot
processes are dynamic structures that contain highly ordered, parallel contractile actin
bundles to modify the permeability of the filtration barrier (Faul et al., 2007). The foot
processes are attached to the GBM and wrap around the capillaries of the glomerulus.
The foot processes from neighbouring podocytes interdigitate to create a series of
“filtration slits” bridged by what is known as the slit diaphragm (Davidson, 2009). The
slit diaphragm is composed of proteins such as nephrin, podocin and podocalyxin. These
foot processes form part of the glomerular filter that allows small molecules (i.e., water,
sugars and electrolytes) to enter the nephron, but retains high molecular weight proteins
and blood cells in the plasma. Without proper functioning of this filter, pathologic
amounts of high molecular weight proteins can be found in the urine, known as
proteinuria. An example of a protein not normally found in large amounts in the urine but
found there in kidney disease is albumin.
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Nucleus'
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Figure 4. Podocyte Morphology. Podocytes are specialized epithelial cells that wrap
around the capillaries of the glomerulus and sit on top of the glomerular basement
membrane. Podocytes are an integral part of the glomerular filter. Podocytes have a cell
body containing the nucleus. Primary processes extend from the cell body and from the
primary processes, there are secondary processes known as foot processes. The foot
processes of neighbouring podocytes interdigitate creating a series of filtration slits
known as the slit diaphragm, which is made of podocyte proteins. The slit diaphragm
helps to fine tune the filtrate from the glomerulus and prevents high molecular weight
proteins and cells from being filtered into the urine.
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1.1.2.1

Podocyte Actin Cytoskeleton

The unique morphology and function of podocytes can be attributed to their actin
dynamics because the foot processes cannot form without the specialized organization of
the actin cytoskeleton (Faul et al., 2007; Kreidberg, 2003). A common pathology
resulting in loss of filtration barrier integrity, proteinuria and kidney disease is foot
process effacement (Faul et al., 2007). Foot process effacement is the process by which
the foot processes of the podocytes flatten and shorten. This creates larger gaps between
the foot processes allowing large molecular weight proteins to leak into the urine. Since
podocyte foot process effacement requires reorganization of the actin cytoskeleton,
proteins that regulate the plasticity of the podocyte actin cytoskeleton are essential in
glomerular filtration barrier function. Some podocyte actin regulating proteins include
Nephrin (Kestilä, 1998), Nck1 and Nck2 (Jones et al., 2006; Verma et al., 2006), STAT3
(Abkhezr and Dryer, 2015), Nef (Tan et al., 2013), Rhophilin-1 (Lal et al., 2014),
Podocalyxin (Takeda et al., 2001), Synaptopodin (Asanuma et al., 2005; Asanuma et al.,
2006) and α-actinin-4 (Henderson, 2008; Kaplan, 2000; Michaud, 2003).
One important protein in the regulation of the podocyte actin cytoskeleton is Ras
homolog family member A (RhoA). One RhoA signaling pathway involves activation of
the Rho-associated coiled coiling forming protein serine/threonine kinases (ROCKI &
ROCKII) (Nakagawa et al., 1996). ROCKs in turn phosphorylate the non-muscle myosin
II regulatory light chain resulting in formation of actin stress fibers (Amano et al., 1996;
Jeruschke et al., 2013). RhoA expression has been shown to promote cell migration in
cultured mouse podocytes (Asanuma et al, 2006). In vivo, RhoA degradation due to
calcineurin overexpression in mice was shown to result in proteinuria thus suggesting an
important role of RhoA in podocyte function. Other in vivo studies corroborate the idea
of RhoA being a positive regulator of normal podocyte function. For instance, it has been
noted that proteoglycan syndecan 4 knockout mice presented with less proteinuria in the
albumin overload model (Liu et al., 2012). The albumin overload model involves daily
injections of albumin, which induces proteinuria (Eddy, 2004). The protein in the urine
consists of both exogenous albumin and endogenous plasma proteins. The fact that
proteoglycan syndecan 4 knockout mice present with less proteinuria is attributed to
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increased RhoA activity in the glomerulus (Liu et al., 2012). Additionally, RhoA in
cultured mouse podocytes was able to decrease cell surface expression of the transient
receptor potential cation channel, subfamily C, member 6 (TRPC6) channel, a known
gain-of-function model that causes focal segmental glomerulosclerosis. With ROCK
inhibition, this beneficial effect of RhoA was reversed. Furthermore, rat models with
puromycin nucleoside nephritis were protected from proteinuria using Everolimus, an
inhibitor of the mammalian target of rapamycin (mTOR) activity (Jeruschke et al., 2013).
mTOR is a known regulator of the actin cytoskeleton in podocytes (Jacinto et al., 2004).
The finding that Everolimus treatment stabilized the actin cytoskeleton was attributed to
stabilization of the actin cytoskeleton via the RhoA/ROCK pathway since there was an
increase in the activity of RhoA, ROCK and myosin light chain (Jeruschke et al, 2013).
As further validation, inhibition of ROCK by Y-27632 resulted in loss of the actin stress
fiber rescue by Everolimus treatment. Taken together, these findings seem to suggest
RhoA is vital in podocyte function.
However, there is controversy about the role of the RhoA pathway in podocyte regulation
and function. Other in vitro studies show inhibition of ROCK results in elongation of the
foot processes in cultured mouse podocytes (Gao et al. 2004; Kobayashi et al. 2004).
Thus suggesting that RhoA may act negatively to regulate aspects of foot process
formation. Other in vivo studies suggest that inhibition of RhoA and ROCK by ROCK
inhibitors fasudil or Y27632, are beneficial to podocyte health and can reverse cases of
proteinuria (Kanda et al., 2003; Kikuchi et al., 2007; Komers et al., 2011; Nishikimi et
al., 2004; Peng et al., 2008; Stirzaker et al., 2012; Sun et al., 2006). Considering the
contrasting results, there is still much work to be done on determining the function of
RhoA and ROCK in podocyte morphology and function. It may be that, at basal
physiological levels, RhoA is important in the maintenance of podocyte function and
glomerular filtration integrity, but when expressed at higher levels, it can induce
podocyte injury and apoptosis (Wang et al., 2012).
An important protein in the RhoA signaling pathway and actin stress fiber formation in
podocytes is Myh9. Myh9 encodes non-muscle myosin heavy chain IIa. Myh9 is a
member of the network of regulators of cytoskeletal organization. Additionally, Myh9

11

was found to be localized to the foot processes in vivo and required for podocyte
cytoskeletal organization in vitro (Hays et al., 2014). SNPs in MYH9 have been
associated with a dramatically increased risk of CKD in West African patients,
particularly glomerular diseases and kidney disease associated with hypertension
(Genovese et al., 2010; Kopp et al., 2008). Even in generally glomerular injury resistant
C57BL/6 mice, a mutation in Myh9 predisposes podocytes to acute injury (Johnstone et
al., 2011). Therefore, Myh9 is an important regulator of the podocyte actin cytoskeleton
and perturbations in its activity may result in glomerular or kidney disease.

1.1.3

Chronic Kidney Disease

Chronic kidney disease (CKD) affects approximately 10% of the population in
industrialized nations and the rate is increasing (Coresh et al., 2007; Hallan et al., 2006;
Zhang & Rothenbacher, 2008). Thus, CKD is a major cause of morbidity and mortality.
CKD is characterized as a gradual loss of kidney function over time (Levey & Coresh,
2012). Since one of the main functions of the kidneys is to remove waste products from
the blood, loss of kidney function can result in the accumulation of waste products to
toxic levels causing illness and death. Furthermore, other complications of kidney disease
include hypertension, anemia (low red blood cell count), weak bones, decreased
nutritional health and nerve damage. Kidney disease generally starts silently, without
symptoms, and progresses slowly over a period of years. According to national
guidelines, CKD is defined as a glomerular filtration rate (GFR) of <60 mL/min/1.73m2
or the presence of one or more markers of kidney damage (e.g., albuminuria,
abnormalities detected by histology) (Levey et al., 2005). The reduction in kidney
function must endure for greater than 3 months to be classified as CKD. There are five
stages of CKD disease with progressive stages characterized by a further reduction in
GFR (Table 1). Albuminuria, measured as urinary albumin to creatinine ratio, can also be
used in the evaluation and diagnosis of CKD (Table 2). CKD can result in end stage renal
disease (ESRD) whereby transplantation or dialysis becomes necessary for survival as the
kidneys are considered to be non-functional and experiencing failure.
Hypertension and diabetes are the largest risk factors for CKD (Fox et al., 2004a; Lash et
al., 2009). However, familial aggregation studies show there is a definite genetic
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component to kidney function. For instance, polycystic kidney disease (PKD) is the most
common genetic cause of ESRD and has a prevalence of 1 in 500 (Lancaster & Gleeson,
2010). There are two forms of PKD, autosomal dominant and autosomal recessive.
Autosomal dominant PKD is caused by mutations in polycystic kidney disease gene 1
(PKD1) and polycystic kidney disease gene 2 (PKD2) which encode polycystin-1 (PC1)
and polycystin-2 (PC2), respectively. Autosomal recessive PKD is a result of mutations
in polycystic kidney and hepatic disease 1 (PKHD1) which encodes fibrocystin (or
polyductin, FPC). Furthermore, there is approximately a 33% heritability of GFR, a key
marker for chronic kidney disease (Fox et al., 2004b). For individuals with major CKD
risk factors, such as diabetes and hypertension, the heritability of GFR increases to
approximately 41-75% (Bochud et al., 2005; Langefeld et al., 2004). Thus, there has been
a considerable focus on determining which genes play key roles in CKD.
Early diagnosis and treatment can often delay progression of CKD. Thus identifying
genetic regulators of kidney development and function may prove beneficial to
preventing or delaying the onset of kidney disease (Levey & Coresh, 2012). In the early
stages of kidney disease, proper diet and medications are able to control electrolyte and
other chemical balances that the kidneys would normally control. Once only 10-15% of
normal function is available, diet and medications are no longer enough and without
proper intervention, patients will progress to ESRD with requirement for dialysis or a
kidney transplant on top of proper diet and medications.
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Table 1. Stages of chronic kidney disease defined by estimated glomerular filtration
rate. Chronic kidney disease results from a reduction in kidney function. Glomerular
filtration rate can act as a marker of kidney function. There are five stages of kidney
disease defined by glomerular filtration rate. Normal glomerular filtration rate is
approximately 120 mL/min/1.73m2. With decreasing estimated glomerular filtration rate,
the poorer the function of the kidneys.
Stage

Estimated glomerular

Function

filtration rate
(mL/min/1.73m2)
1

>90

Normal or high

2

60-89

Mildly decreased

3a

45-59

Mildly to moderately
decreased

3b

30-44

Moderately to severely
decreased

4

15-29

Severely decreased

5

<15

Kidney failure
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Table 2. Kidney damage assessment by albumin levels in the urine. A key marker of
chronic kidney disease is increased levels of albumin in the urine. Albumin levels are
generally given as a ratio of albumin to creatinine to control for the concentration/dilution
of the urine. The greater the level of albumin in the urine, the greater the kidney damage
and subsequent poor prognosis.
Terms

Male albumin to

Female albumin to

creatinine ratio (mg/g)

creatinine ratio (mg/g)

Normal to mildly increased

<20

<30

Moderately increased

20-200

30-300

Severely increased

>200

>300
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1.1.4

Genome-wide Association Studies

A number of genome wide association studies (GWAS) have recently been performed to
find genes that are associated with kidney dysfunction and disease. One gene that has
emerged through these studies is SHROOM3. At the time these GWAS emerged, there
was very little known about SHROOM3 other than that it was expressed in Xenopus
pronephric kidney (Lee et al., 2009) and that based on its role in other organ systems, it is
involved in tissue morphogenesis. In four large randomized population-based studies
from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE)
consortium, SHROOM3 was the second of three loci to have the highest association with
estimated creatinine glomerular filtration rate (eGFRcrea) (Köttgen et al., 2009). The
others were Uromodulin (UMOD), a gene known to cause kidney disease when mutated,
and Jagged 1 (JAG1), that when mutated causes Alagille syndrome that can affect the
kidneys. Additionally, another GWAS examined participants of European descent
(CKDGen Consortium) and African-American descent (CARe Renal Consortium) (Ellis
et al., 2012). A specific SNP in SHROOM3, rs17319721 A allele, was found to be
associated with lower urinary albumin-to-creatinine ratio (UACR) in both ethnic groups.
The rs17319721 SNP is found within the first intron of SHROOM3. Furthermore, this
SNP in SHROOM3 accounted for almost the entire association with albuminuria with
respect to all genes analyzed by the GWAS.
Other promising GWAS examined type 2 diabetic patients in the Genetics of Diabetes
Audit and Research Tayside (GoDARTs) study (Deshmukh et al., 2013). Diabetes is a
major risk factor for CKD. SHROOM3 was found to be one of three loci associated with
estimated glomerular filtration rate (eGFR) in type 2 diabetics. More specifically,
SHROOM3 was found to have a greater association to type 2 diabetic patients with levels
of albuminuria compared to those patients with sustained normalbuminuria.
Lastly, another study examined European descent participants from the CHARGE
Consortium. The participants were studied for correlations with serum magnesium,
potassium and sodium concentrations (Meyer, 2010). The kidney is important in
regulating these ionic concentrations in the serum. SHROOM3 was one of six loci found
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to be significantly associated with serum magnesium concentrations and clinical
hypomagnesemia.
These GWAS strongly suggest that SHROOM3 may be a potential genetic player in
kidney function and CKD. However, GWAS studies are purely correlational. It is
important to provide experimental evidence to prove or disprove causation between loss
or hypmorphic expression of Shroom3 and detriment to kidney morphology, development
or function. More specifically, the GWAS do not elude to which cell types express
SHROOM3 and by extension, what sorts of defects would result in kidney disease. By
defining a role for Shroom3 in the kidney, it may be a means of determining patients at
risk for adult kidney disease. With proper diet and medication, these individuals may be
able to circumvent or slow the complications of CKD.

1.2 Shroom3
1.2.1

Gene trap mutagenesis

Gene trap mutagenesis involves insertion of DNA with a splice acceptor site in front of a
reporter construct into a target gene such that the endogenous promoter drives normal
expression (Friedrich & Soriano, 1991). The splice acceptor site causes the reporter gene
to be expressed at the same time if the insertion results in the reporter being in frame with
endogenous gene. Thus, the inserted reporter can act as an indicator of where the
endogenous gene is normally expressed. In most cases the insertion also disrupts the
coding sequence of the endogenous gene creating a loss of function allele. Many of these
constructs involve insertion and fusion of the Escherichia coli lacZ gene, which produces
β-galactosidase (Skarnes et al., 1992). β-galactosidase is an enzyme that can hydrolyze
lactose. β-galactosidase expression can easily be visualized via X-gal (or BCIG, 5bromo-4-chloro-3-indolyl-β-D-galactopyranoside) staining. X-gal acts as an analog of
lactose and can be hydrolyzed by β-galactosidase. A product of this hydrolysis dimerizes
and is oxidized by ferric and ferrous ions to produce an insoluble blue precipitate. Thus, a
blue stain will appear where the endogenous gene is expressed.
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1.2.2

What is Shroom3?

Shroom was originally identified by gene trap mutagenesis in mice due to a 100%
penetrant exencephaly in mutant mice containing two copies of the gene trap. Initial
characterization of the protein sequence and phenotype was completed by Hildebrand and
Soriano (1999). In the mutants, the brain essentially “mushrooms” out of the skull and
that observation is how Shroom received its name. Shroom was later renamed Shroom3
due to the discovery and sequence homology of Apx/Shrm (ASD) domains in three other
proteins (Hagens et al., 2006). The gene trap, containing the lacZ gene, is inserted
between the third and fourth exon of Shroom3, which is believed to be effective in
truncating the protein and making it non-functional (Figure 5). As verification that this
gene trap prevents normal Shroom3 function, antibodies to the C-terminus of the protein
reveal no Shroom3 present (Hildebrand & Soriano, 1999). This gene trap inserts lacZ into
the Shroom3 locus allowing use of simple X-gal staining for examination of Shroom3
expression.
Shroom3 has three conserved domains: two Apx/Shrm domains (ASD1 and ASD2) and a
PSD-95/Dlg1/ZO-1 (PDZ) domain (Hildebrand & Soriano, 1999). The central ASD1
domain is known to directly bind to F-actin (Hildebrand & Soriano, 1999) whereas the Cterminal ASD2 domain directly binds the Rho-associated kinases 1 & 2 (ROCK1 &
ROCK2) (Figure 6) (Nishimura et al., 2008). These interactions with actin and ROCK are
essential for the ability of Shroom3 to drive apical constriction of epithelial cells. The Nterminal PDZ domain is thought to be dispensable to Shroom3’s ability to drive apical
constriction (Hildebrand & Soriano, 1999) because mice contain two isoforms of
Shroom3 and the shorter isoform without the PDZ domain seems to have the same
functionality as the longer isoform containing the PDZ domain. Thus, the PDZ domain
has no currently known role in Shroom3 function, but given conservation of this region,
an undiscovered role for this domain may exist. Shroom3 is found at adherens junctions
where it co-localizes with β-catenin and F-actin (Hildebrand & Soriano, 1999).
Shroom3 is a member of the Shroom family of proteins which consists of 4 members
based on conservation of ASD domains: Shroom1 (formerly known as apical protein
Xenopus, APX), Shroom2 (formerly known as apical protein Xenopus-like, APXL),

18

Shroom3, and Shroom4 (formerly known as KIAA1202) (Hagens et al., 2006). These
proteins are found in unique as well as overlapping tissue types and have all been shown
to regulate the actin or microtubule cytoskeleton resulting in tissue morphogenesis (Lee
et al., 2009). The other Shroom proteins seem unable to fully compensate for the loss of
Shroom3 because there is still failure of neural tube closure when Shroom3 is lost in vivo
(Hildebrand & Soriano, 1999). Thus, Shroom3 appears to have unique functions although
part of a family of Shroom proteins.
Shroom3 is a highly conserved protein found in all vertebrates examined including
Xenopus, zebrafish, mouse, rat, chick and humans. Shroom3 is not ubiquitously
expressed (Hildebrand & Soriano; Lee et al., 2007). For example, Shroom3 is expressed
in the lens placode, neural tube, heart and gut. The human SHROOM3 is found on
chromosome 4 at locus at 4q21.1 and is 348.22 kb in length. Humans contain one isoform
of SHROOM3 that is 1996 amino acids in length. Current evidence does not suggest any
other isoforms of SHROOM3 in humans. The mouse Shroom3 is located on chromosome
5 and covers 282.40 kb. Mice have two known isoforms of Shroom3, a longer and shorter
isoform. The longer isoform is 1986 amino acids in length whereas the shorter isoform
lacks the N-terminal 175 amino acids (Hildebrand & Soriano, 1999).
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Figure 5. Schematic of Shroom3 gene trap. The gene trap is inserted between exon 3
and 4 of Shroom3 resulting in a truncated, and non-functional protein. The gene trap
inserts lacZ which allows for the product, β-galactosidase, to act as a reporter of where
endogenous Shroom3 expression occurs by X-gal staining. There is a splice acceptor site
in front of lacZ to allow it to be in frame with the Shroom3 protein, Cre recombinase, and
a poly-A tail.
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Figure 6. Schematic of conserved domains of Shroom3. Shroom3 has three conserved
domains: a PSD/Dlg1/ZO-1 (PDZ) domain, and 2 Apx/Shrm (ASD) domains (ASD1 &
ASD2). The PDZ domain is thought to be dispensable to Shroom3’s ability to stimulate
apical constriction. ASD1 is known to directly bind F-actin while ASD2 is known to
directly bind to ROCK1/ROCK2.
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1.2.3
1.2.3.1

Shroom3 Function
Apical Constriction

The actin cytoskeleton is made of single subunits called globular actin, or G-actin, that
polymerizes into chains (Michelot & Drubin, 2011). Two chains of G-actin intertwine
forming what is known as filamentous or F-actin. The actin cytoskeleton, made up of Factin, is integral to the structure of the cell and for cell shape as well as cell motility,
endocytosis and cytokinesis. An important cell shape change requiring the rearrangement
of the actin cytoskeleton is apical constriction. Apical constriction involves contraction of
the actin at the apical surface of epithelial cells decreasing the surface area and causing
the cell to become wedge-shaped (Figure 7).
Shroom3 expression can drive apical constriction within a cell and this constriction is
crucial in a number of different contexts including the closure of the neural tube (Das et
al., 2013; Hildebrand & Soriano, 1999; Nishimura et al., 2008), invagination of the lens
pit (Plageman et al., 2010; Plageman et al., 2011a) and creation of the V-shaped
morphology of the archenteron roof for subsequent gut morphogenesis (Chung et al.,
2010). Shroom3 drives apical constriction when localized to the apical surface. This
localization is dependent on RhoA as evidenced in the lens pit in mouse and chick
embryos as well as in vitro studies (Plageman et al., 2011a). Furthermore, Trio acts as a
RhoA-guanine exchange factor (GEF). Trio is required for the activation of RhoA and
subsequent Shroom3-mediated apical constriction. Therefore, to initiate apical
constriction, there is a Trio-RhoA-Shroom3 pathway.
Shroom3, once activated by RhoA, then binds directly to the Rho-associated kinases,
ROCK1 & 2, via the ASD2 domain (Das et al., 2013; Nishimura et al., 2008). ROCK
activation and localization to the apical region then allows phosphorylation of the nonmuscle myosin II regulatory light chain (pMLC) (McGreevy et al., 2015; Nishimura et
al., 2008). The myosin moves along actin and causes contraction of the actin at the apical
surface resulting in reduced apical surface area and apical constriction.
The most pronounced phenotype of mice lacking Shroom3 function is a failure of
convergence of the neural folds at the dorsal midline resulting in exencephaly
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(Hildebrand & Soriano, 1999). This failure of convergence is due to loss of Shroom3
driven apical constriction in the neural plate. Because of this severe 100% penetrant
phenotype in mice homozygous for the gene trap, homozygous mice suffer perinatal
lethality. Of interest is an 8% penetrance of exencephaly in heterozygotes, demonstrating
a phenotype with hypomorphic Shroom3 function. Other notable, gross morphological
defects seen in the original description of the homozygous gene trap mice include
acraniofacial clefting, spina bifida, and herniation (Hildebrand & Soriano, 1999).
Folic acid has now become a highly recommended supplement for pregnant women and
women who plan to become pregnant because it has been shown to decrease the rate of
neural tube defects (NTDs) (Massaro & Rogers, 2002). A paper examining the ability of
folic acid supplementation to prevent NTDs caused by specific genetic mutations in mice
demonstrated that some genetic defects are rescued by folic acid supplementation
(Marean et al., 2011). One mouse model examined was a novel mutation in Shroom3.
These mice possess an ENU-induced mutation, Shroom3C5745T, whereby there is a C to T
mutation in the codon for amino acid 1663 within exon 9 causing a change from arginine
to cysteine. This Shroom3 mutation has the same phenotype as the gene trap mutation
providing verification that the gene trap creates a null allele. Mice heterozygous for
Shroom3C5745T were bred together and the pregnant females were fed a diet with folic acid
supplementation (Marean et al., 2011). Importantly, duration of folic acid
supplementation seemed to play a key role in the incidence of NTDs in the Shroom3
mutants. Long-term folic acid supplementation proved to be detrimental whereby there
was an increase in mutant embryo loss prenatally as evidenced by reabsorption sites.
However, short-term folic acid supplementation seemed to be beneficial as there was a
decrease in Shroom3 mutant embryo loss and a reduction in NTDs. Therefore, with
respect to Shroom3, it seems there is a complicated environmental influence on Shroom3
activity and different levels of environmental exposure may be able to correct defects in
hypomorphs or mutants.
Shroom3 is important for normal morphogenesis of the lens. Shroom3 induces lens
epithelial cells to undergo apical constriction to create the lens pit (Plageman et al., 2010;
Plageman et al., 2011a). It has been found that in mouse and zebrafish retinal
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neuroepithelial cells that lack the Lethal(2) giant larvae protein homolog 1 (Llgl1) result
in expanded apical domains, similar to loss of Shroom3 (Clark et al., 2012). Moreover,
like Llgl1, loss of Shroom3 increased Notch activity and decreased neurogenesis. Thus,
regulation of Notch activity may be an important function of Shroom3 and should be an
area for future study.

1.2.3.2

Apicobasal Elongation

Shroom3 not only affects the actin cytoskeleton, it can also change microtubule
architecture (Lee et al., 2007). Microtubules are macromolecular structures that are made
of two subunits, α-tubulin and β-tubulin (McCarroll & Kavallaris, 2012). These subunits
form a heterogeneous dimer that then polymerizes to form long microtubule structures.
Microtubules are highly dynamic and are important in a number of cell shape changes
including the movement of chromosomes during mitosis. Another important member of
the tubulin superfamily is γ-tubulin. Gamma-tubulin can be found to act as a microtubule
organizing center, but is most often found distributed throughout the cytoplasm (Patel &
Stearns, 2002). The function of γ-tubulin is to nucleate microtubules and thereby control
when and where microtubules polymerize.
Shroom3 is necessary and sufficient to cause apical localization of γ-tubulin in epithelial
cells (Lee et al., 2007). This localization then causes thickened robust apicobasal
rearrangement of the microtubules and elongation of the cell known as apicobasal
elongation (Figure 7). This elongation causes the cell to increase in height. However, how
Shroom3 causes apical localization of γ-tubulin remains unknown as there does not
appear to be a direct interaction between the two proteins. This should be an area of
future study that will help further elucidate how Shroom3 regulates cell morphology.
Another developing organ that requires Shroom3 activity is the gut. Within the gut,
Shroom3 is required for normal apicobasal elongation of cells and ectopic expression of
Shroom3 can drive this elongation process (Chung et al., 2010). Furthermore, Shroom3 is
required for maintenance of pseudostratification of the intestinal epithelium whereby
microtubule-dependent apicobasal elongation maintains a single layer for proper
morphology (Grosse et al., 2011). Thus, both apical constriction and apicobasal
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elongation are important for proper gut morphogenesis and Shroom3 is important in the
regulation of those cellular changes.
Another cell type where Shroom3 regulates cell morphology is the axon process of
neurons (Taylor et al., 2008). Shroom3 works with the scaffold protein Plenty of SH3s
(POSH) to negatively regulate axon outgrowth as loss of either Shroom3 or POSH causes
axon outgrowth. Shroom3 interacts with the third Src homology (SH) 3 domain of POSH
and the Shroom3-POSH complex seems to act through myosin II to inhibit neuronal
process outgrowth. Therefore, Shroom3 may play a role in the plasticity of the central
nervous system and could be a potential therapeutic target to enhance axon outgrowth.
Interestingly, it seems Shroom3 inhibits, rather that induces, cell shape changes in the
axon.
Finally, Shroom3 has been linked to left-right patterning of the body (Tariq et al., 2011).
Using whole exome sequencing, a missense mutation was identified in SHROOM3 in a
heterotaxy patient and this mutation was predicted to be causative. Further analysis in
additional heterotaxy patients revealed other potentially pathogenic variants of
SHROOM3. The mechanism by which Shroom3 might alter left-right patterning still
needs to be elucidated and whether that activity has any relation to the apicobasal
elongation or apical constriction of specific cell types.
Although a cell may express Shroom3, apical constriction and apicobasal elongation
appear to be at least partially independent. Some organs may undergo apical constriction,
but not apicobasal elongation (Lee et al., 2007). Furthermore, Shroom1 and Shroom2 can
drive apicobasal elongation of cells, but not significant apical constriction (Fairbank et
al., 2006; Lee et al., 2007). Therefore, Shroom3 acts in a complex manner to effect cell
and subsequently tissue morphogenesis by apical constriction and/or apicobasal
elongation. It will be important to determine regulators of Shroom3 activity that may
explain why particular cells undergo either apical constriction, apicobasal elongation or
both.
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Figure 7. Shroom3 alters cell shape to regulate tissue morphogenesis. Shroom3
(purple) dependently on RhoA (not shown) can localize to the apical surface of epithelial
cells. Shroom3 can bind directly to ROCKs (blue) via its ASD2 domain causing apical
localization of ROCK. ROCK will then phosphorylate the non-muscle myosin II
regulatory light chain (white) which will move along actin (red) and cause apical
constriction producing a wedge-shaped cell. Shroom3 can also drive apicobasal
elongation via indirect interaction with γ-tubulin (yellow) causing apical localization of
γ-tubulin. γ-tubulin causes the arrangement of microtubules in an apical basal manner.
These microtubules become more robust and the cells elongate along the apical basal
plane resulting in a taller cell. Thus, Shroom3 is involved in two specific cellular
processes necessary for proper tissue morphogenesis.
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1.2.4

Shroom3 Regulation

Shroom3 is important in specific cell shape changes and subsequent tissue
morphogenesis. However, there is still very little known about how Shroom3 is regulated
in different organs. The proteins that have been shown to be associated with Shroom3
regulation are primarily tissue-specific transcription factors suggesting that how Shroom3
is regulated will vary depending on the tissue being examined.
During lateral line morphogenesis, rosettes are formed to allow for proper alignment and
organization of the cells. The lateral line is a mechanosensory system made of
neuromasts, which allows for the detection of water movements. Rosette formation is
controlled by fibroblast growth factor (fgf) signaling. Specifically in the back two-thirds
of the posterior lateral line, fibroblast growth factor receptor 1 (fgf1r) is present and is
activated by fibroblast growth factor 3 (fgf3) and fibroblast growth factor 10 (fgf10). It
has been shown that Shroom3 is downstream of fgf signaling in zebrafish lateral line
primordium and that Shroom3 is required for the proper apical constriction to allow
rosette formation (Ernst et al., 2012). Therefore, fgf signaling is required for Shroom3
rosette formation in the lateral line.
An upstream regulator of Shroom3 in the neural tube is Lulu (Chu et al., 2013). Similar
to the requirement for Shroom3 in apical constriction in the neural tube, loss of Lulu
results in improper neural tube closure. Furthermore, in Xenopus, Lulu is required for
Shroom3-dependent apical constriction of neural tube cells as loss of endogenous Lulu
resulted in failure of apical localization of Shroom3 and loss of apical constriction.
Therefore, for apical constriction of the neural tube, Lulu is an important upstream
regulator of Shroom3.
An important example of apical constriction, other than in the neural tube, is the
invagination of the lens placode to create the lens pit (Plageman et al., 2010; Plageman et
al., 2011a). The apical constriction of the epithelial cells of the lens requires Shroom3.
Shroom3 expression in the lens placode of mice and zebrafish is dependent on Pax6, a
critical transcription factor in defining the lens (Plageman et al., 2010). Furthermore, in a
murine model, p120-catenin is required for Shroom3 localization to the adherens junction
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in the eye to allow for proper apical constriction of the lens cells (Lang et al., 2014).
Thus, p120-catenin and Pax6 may be important lens-specific regulators of Shroom3.
Shroom3 is required for normal gut morphogenesis and it appears that Pitx1, and other
members of the Pitx family of transcription factors (Pitx2 and Pitx3), can directly activate
transcription of Shroom3 in the Xenopus gut (Chung et al., 2010). Ectopic expression of
Pitx1 causes Shroom3 expression and apicobasal elongation within naive cells.
Additionally, in a mouse model, Pitx2 and Shroom3 are required for proper left
downward tilting of the dorsal mesentery (DM) of the early midgut (Plageman et al,
2011b). This tilting is required for proper coiling of the gut tube. Loss of either Pitx2 or
Shroom3 results in the same phenotype which is shortening and widening of the cells of
the left DM. Furthermore, N-cadherin expression is Pitx2 dependent and found only
within the left side of the gut. Therefore, it seems that Shroom3 works cooperatively
with N-cadherin to directly regulate cell shape changes. Therefore, in the gut, Pitx
proteins are required directly or indirectly for Shroom3 function.
Shroom3 also plays a role in axon outgrowth. It has been found that Nogo66, a domain of
NogoA, signals through Paired Ig-like Receptor B (PirB) to inhibit neuronal process
outgrowth (Dickson, 2010). NogoA is a protein found in central nervous system myelin
and is known to limit axon outgrowth and plasticity (Dickson et al., 2010; McGee et al.,
2005; Mignorance-Le Meur et al., 2007). It has been noted that POSH is required to relay
the signal downstream of Nogo66 (Dickson, 2010). POSH is a scaffold protein that
regulates axon outgrowth (Taylor et al., 2008). Through previous work it has been shown
that POSH forms a complex with Shroom3 in axons and this complex acts on myosin II
to inhibit process outgrowth. By extension, Shroom3 may also be regulated by Nogo66
and the PirB receptor to inhibit axon outgrowth of neurons (Taylor et al., 2008).
For proper neural tube closure, convergent extension is required whereby the cells extend
along the anterior-posterior (AP) axis. Convergent extension requires the planar cell
polarity (PCP) pathway that creates polarized cells and is essential in the organization of
epithelial structures (Gubb & García-Bellido, 1982; Wong & Adler, 1993). The PCP
pathway is a non-canonical Wnt signaling pathway, meaning that it is independent of β-
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catenin (Schnell & Carroll, 2014). In vertebrates, disruption of the PCP pathway gives
rise to embryos with shortened AP axes and NTDs (Ciruna et al., 2006; Wallingford &
Harland, 2002; Ybot-Gonzalez et al., 2007). PCP proceeds via binding of Wnt ligands to
Frizzled (Fzd) membrane receptors which transduces the signal via the cytoplasmic
Dishevelled (Dvl) proteins (Heisenberg et al., 2000; Kilian et al., 2003; Qian et al., 2007;
Tada & Smith, 2000; Wu et al., 2013). Dvl goes on to activate the small GTPase Rho that
activates ROCK and MLC to induce polarized cytoskeletal arrangements (Habas et al.,
2001; Marlow et al., 2002; Winter et al., 2001). Other core components in the PCP
pathway include Vang-like protein 2 (Vangl2; also known as Lpp1 and Ltap) (Gao et al.,
2011; Montcouquio et al., 2003), Prickle (Jenny et al., 2007; Tree et al., 2002) and
Flamingo (Carreira-Barbosa et al., 2009). Recent evidence suggests that Shroom3 is part
of the PCP pathway during neural tube closure in mice (McGreevy et al., 2015). Shroom3
was shown to interact with Vangl2 and directly interact with segment polarity protein
dishevelled homolog (Dvl2). Shroom3 interacts with Dvl2 via the DEP domain of Dvl2
and an uncharacterized region between the serine-proline rich region and the ASD1
domain of Shroom3 (McGreevy et al., 2015). PCP is upstream of Shroom3 as Dvl2
remains properly polarized in Shroom3Gt/Gt mice. Dvl2 can also regulate the localization
of the Shroom3-ROCK complex that may indicate at how PCP can localize MLC
activity. Thus, members of the PCP pathway can regulate Shroom3, at least within the
neural tube. Importantly, the PCP pathway is also an important component of kidney
morphogenesis (Papakrivopoulou et al., 2014).
In summary, a number of tissue-specific regulators of Shroom3 have been identified in
several contexts however, in other tissues where Shroom3 is expressed, such as the
kidney and heart, regulators are still not known. Future research should continue to focus
on determining potential organ-specific factors. Furthermore, it would be interesting to
determine if known tissue-specific regulators in fact regulate Shroom3 in other organs
where Shroom3 is expressed.

1.2.5

Shroom3 and the kidney

At the time I began my Master’s project, the only articles pertaining to Shroom3 in the
kidney were the GWAS studies and one Xenopus expression paper (Lee et al., 2009). I
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began this project in order to elucidate a mechanistic explanation of the observations that
Shroom3 is important in the development of the kidney. A number of research articles
have recently emerged on this topic.
In a recent paper, the Fawn-Hooded Hypertensive (FHH) rats were analyzed with the
hypothesis that Shroom3 function (Yeo et al., 2015) is related to the spontaneous kidney
injury and albuminuria that is common in this rat line (Shiozawa et al., 2000). The FHH
phenotype was found to be in part caused by a mutation within the ASD1 binding domain
of Shroom3, preventing interaction of Shroom3 with actin (Yeo et al., 2015). Introduction
of the Brown Norway (BN)-derived region of chromosome 14 containing normal
Shroom3 into the FHH rats resulted in improved glomerular structure and decreased
levels of albuminuria in the congenic rats. Furthermore in the same study, it was noted
that Shroom3 is expressed in the pronephros of zebrafish. With morpholino knockdown
of Shroom3, there appeared to be evidence of kidney impairment evidenced by cardiac
edema in the zebrafish. The zebrafish also displayed compromised pore selectivity
because following FITC dextran injection into the circulation, there was a reduction in
FITC signal intensity in the dorsal aorta after 24 and 48 hours. With injection of BN
Shroom3 mRNA into the zebrafish, but not FHH mRNA, there was a rescue of the
hypothesized glomerular defects. Additionally, transgenic zebrafish expressing a
dominant negative Shroom3, specifically in the podocytes, resulted in loss of filtration
integrity as well as podocyte foot process effacement suggesting Shroom3 is necessary
for podocyte integrity. A dominant negative mutation results in a gene product that
adversely affects the activity of the gene even in the presence of normal wild-type gene
product.
In another recent article, recipients and donors for renal allografts were compared in a
study named GoCAR (Menon et al., 2015). The SHROOM3 SNP, rs17319721 with a G to
A transition, is associated with CKD and was present in 36.66% of recipients and 39.94%
of donors within the Caucasian community. There was an insufficient distribution of the
A allele in non-Caucasian participants and thus the allele was more prevalent in the
Caucasian population. Donors, but not recipients, with the SNP resulted in higher
allograft expression of SHROOM3 at 3 months both in heterozygous and homozygous
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donors for the SNP. Furthermore, allografts from donors with the A SNP were associated
with decreased eGFR and greater allograft dysfunction at 12 months, but this association
was only demonstrated for Caucasian donors.
A novel mechanism of Shroom3 action was determined in the kidney tubules. The A
allele was noted to preferentially bind transcription factor 7-like 2 (T-cell specific, HMGbox) (TCF7L2) that is bound to β-catenin resulting in activation of gene transcription
(Menon et al., 2015). TCF7L2, also known as TCF-4, is a transcription factor that is part
of the WNT signaling pathway and acts as a nuclear receptor for β-catenin (Weedon,
2007). WNT signaling is critical for embryonic development, cellular proliferation, cell
migration and, because of TCF7L2, glucose homeostasis. TCF7L2 has been found
through a number of GWAS to be the most significant genetic indicator of risk for Type 2
diabetes (Diabetes Genetics Initiative of Broad Institute of Harvard and MIT et al., 2007;
Grant et al., 2006, Scott et al., 2007; Sladek et al., 2007; Zeggini et al., 2007). Two copies
of a common variant results in a 2-fold increased risk of Type 2 diabetes. Furthermore,
transforming growth factor beta 1 (TGFβ1) expression was shown to induce SHROOM3
expression in vitro in a β-catenin/TCF7L2 dependent manner (Menon et al., 2015).
TGFβ1 is a secreted ligand that binds to TGFβ receptors in the cell membrane (HermanEdelstein et al., 2013). This binding leads to intracellular signals resulting in many
physiological, developmental and pathological processes, including renal fibrosis. It has
been noted by many groups that TGFβ upregulation is found in virtually all cases of
chronic kidney disease in both animal and human models (Böttinger & Bitzer, 2002;
Herman-Edelstein et al., 2011; Lee, 2012; Wang, 2011). This in turn facilitates canonical
TGFβ1/Mothers Against Decapentaplegic Homolog 3 (SMAD3) signaling by SHROOM3
that enhances profibrotic gene expression both in vitro and in vivo in a murine model
resulting in tubulointerstitial fibrosis that generally results in CKD (Menon et al., 2015).
Therefore, both these papers suggest, similar to my work, that loss of Shroom3 is
detrimental to kidney development and function.

1.3 Rationale and Hypothesis
The purpose of this thesis is to identify a causal relationship between Shroom3 and
kidney function that has been suggested by the GWAS studies. The focus was on
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examining where and when Shroom3 is expressed in the kidney, and the phenotypes
associated with loss of Shroom3 function. An important area of this thesis was to
examine if there are phenotypes associated with a heterozygous phenotype that would be
representative of hypomorphs for SHROOM3 function in the human population. As we
would not expect humans to have complete loss of SHROOM3 function due to the
exencephaly phenotype observed in mice, it is important to elucidate whether decreased
Shroom3 activity could result in kidney dysfunction.
This thesis was done in collaboration with Hadiseh Khalili from Dr. Darren
Bridgewater’s lab at McMaster University. From preliminary studies done in our lab and
with our collaborator, we have shown that Shroom3 is localized to specific cells of the
kidney, such as the podocytes, cap mesenchyme and collecting duct. The focus of my
research was on the podocytes since the actin cytoskeleton is vital to podocyte function
and Shroom3 is an actin-binding protein. I sought to determine if Shroom3 is important
in the dynamic regulation of the foot processes of podocytes. Given Shroom3 expression
in the podocytes, I hypothesize that Shroom3 is necessary for normal podocyte foot
process formation and that with loss or decreased Shroom3 expression, there will be
impairment of podocyte function and thus loss of the integrity of the filtration barrier in
the kidney. This will result in kidney defects including proteinuria and potentially CKD
and ESRD. Therefore, I hypothesize that Shroom3 is an important regulator of podocyte
development and function and reduced Shroom3 activity results in CKD.
Although recent articles have been published about Shroom3 function in the kidney, none
have used a mouse model that is known to have a clearly identified mutation in Shroom3
or examined its role from the beginning of development. This is important, as
hypomorphs for SHROOM3 in the human population would have decreased SHROOM3
activity throughout development. Furthermore, although there was a brief mention of
podocytes in one paper (Yeo et al., 2015), the consequences of Shroom3 loss on the
development and function of podocytes was not examined. Additionally, nothing is
known about the expression of Shroom3 during kidney development. Thus, my thesis
helps answer many important questions about Shroom3 in the kidney. My results show
that mice heterozygous and homozygous for loss of Shroom3 show glomerular defects
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and decreased number of glomeruli. I provide a potential mechanism for the loss of
podocytes due to a loss of apical ROCK1 and pMLC in mice heterozygous and
homozygous for the Shroom3 mutation. This results in a loss of apical actin in some
podocytes and this loss could result in loss of glomeruli. In adulthood, some of the
Shroom3 heterozygotes show functional deficits as evidenced by proteinuria. Therefore,
my results show that Shroom3 is an important regulator of normal glomerular and
podocyte development and function and that reduced Shroom3 activity can result in
CKD.
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Chapter 2

2

Materials and Methods

2.1 Shroom3 gene trap mice
The Shroom3 gene trap mice (B6.129S4-Shroom3Gt(ROSA53)Sor/J) were purchased
from the Jackson Laboratory (Bar Harbor, Maine). The mice contain the original gene
trap (Hildebrand and Soriano, 1999) used to characterize the protein, but have since been
bred to a congenic C57BL/6 background. The gene trap line was created by inserting the
cassette SAβgalCrepA between the third and fourth exon of Shroom3. This cassette
contains: an adenovirus splice acceptor (Friedrich and Soriano, 1991), a fusion creating a
bifunctional gene between β-galactosidase (β-gal) and Cre recombinase, and the MC1
polyadenylation (pA) sequence (Thomas and Capecchi, 1987). For mice containing the
gene trap allele of Shroom3, the shorthand Gt will be used for this thesis. The mice were
housed in a specific pathogen free facility at the Victoria Research Laboratories.

2.2 Mouse embryo collection
All experiments for this thesis (Xenopus laevis and murine) were approved by the Animal
Care Committee at the University of Western Ontario Canada (Protocol #: 2011-015).
Mice were handled according to the regulations laid out by the Canadian Council on
Animal Care (CCAC). Timed pregnancies were performed using a heterozygote male and
either a heterozygote or wild-type female. Vaginal checks were performed the morning
after mating to look for the presence of vaginal plugs, which would indicate a time point
of embryonic day (E) 0.5. Pregnant dams were euthanized at varying time points using
carbon dioxide (CO2). Embryo age was determined using Theiler staging (Theiler, 1972;
Theiler, 1989). The females were dissected and embryos were removed and washed in 1×
PBS.

2.3 Adult mouse kidney collection
Adult wild-type and heterozygous mice were grown up to varying ages (between 1 month
and 3 months of age) and euthanized by CO2. The kidneys were removed, rinsed in 1x
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PBS, and halved longitudinally for later analysis.

2.4 Genotyping
The genotypes of adult and embryonic mice were determined using polymerase chain
reaction (PCR) of ear clip or tail DNA. To purify DNA, tissues were submerged in tissue
lysis buffer (100mM Tris-Cl pH 8.5, 5mM EDTA pH 8.0, 200mM NaCl, 0.2% SDS
(w/v) in dH2O) containing 100µg/mL of Proteinase K overnight at 55°C. The next
morning the DNA was separated from protein using phenol/chloroform extraction. In
order to detect the gene trap allele in mutants and heterozygotes, the forward primer F11
(5’- GGTGACTGAGGAGTAGAGTCC -3’) and reverse primer R1 (5’GAGTTTGTGCTCAACCGCGAGC -3’) were used. To detect the wild-type allele, the
forward primer F11 and the reverse primer R4 (5’GCAACCACATGGTGGGAGACAAGC -3’) were used. The PCR parameters were as
follows for 30 cycles: 95°C for 45 seconds, 60°C for 45 seconds, and 72°C for 45
seconds. The expected amplicon size of the gene trap allele is 1500 bp and the expected
amplicon for the wild-type allele is 1000 bp.

2.5 Whole-mount X-gal staining
Whole-mount X-gal staining was performed on entire kidneys from E11.5 to E18.5 as
well as adult kidneys. In order to show specificity of X-gal staining, wild-type
counterparts were stained simultaneously and were expected to lack blue colouration.
Samples were washed in PBST (PBS + 1% Triton-X) then fixed for 1 hour in 4% PFA
(4% paraformaldehyde (w/v) in dH2O, 100mM Hepes, 10mM NaCl) at room
temperature. Following fixation, the embryos were left in PBST for at least an hour
(depending on the sample thickness). Samples were then placed in X-gal staining solution
(0.5mg/mL X-Gal in dimethyl formamide, 400µM potassium ferricyanide, 400µM
potassium ferrocyanide, 2mM MgCl2) dissolved in PBST and left overnight or up to 24
hours at 37°C. Following staining, the samples were washed with PBS and then fixed for
another hour in 4% PFA at room temperature or overnight at 4°C. To image the X-gal
staining, whole-mount X-gal samples were placed under a Leica MZ12 dissecting
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microscope and images were taken using Northern Eclipse Software (Empix Imaging;
Mississauga, ON, Canada).

2.6 Xenopus embryo collection and fixation
Adult frogs were obtained from Xenopus 1 (Dexter, MI). To obtain embryos, female
Xenopus laevis were injected the previous night with 500 to 700 IU of human chorionic
gonadotropin (Sigma) to induce ovulation the next morning. To retrieve eggs, females
were squeezed and the eggs were fertilized in vitro using minced testes in 80%
Steinberg’s solution. Fertilization was allowed to occur and then embryos were de-jellied
using a 2.5% cysteine solution (pH 8.0). Embryos were subsequently grown in 20%
Steinberg’s solution. Staging of the embryos was via the Nieuwkoop and Faber staging
table (Nieuwkoop & Faber, 1994).
Xenopus laevis embryos were fixed at stage 33/34 to examine pronephros staining and
stage 48 to examine mesonephros staining. Fixation was done by immersing the embryos
in MEMPFA (4% PFA in dH2O, 1mM MgSO4, 100mM Mops pH 7.5, 2mM EGTA pH
8.0) for 2 hours at room temperature or overnight at 4°C. Storage of embryos was in
100% methanol and left at 4°C or -20°C. At stage 48, the heads of the embryos were
removed using a razor blade prior to in situ hybridization to increase probe penetration
and reduce background staining of the head at these later stages.

2.7 Whole-mount in situ hybridization
The protocol for whole-mount in situ hybridization for Xenopus embryos was based on
Deimling et al. (2015). However, for the mouse kidney in situs, a different mousespecific RNA hybridization buffer was used: 1x salts solution (0.2M NaCl, 5mM EDTA,
10mM Tris-HCl pH 7.5, 5mM NaH2PO4, 5mM Na2HPO4), 50% formamide, 0.1mg/mL
yeast tRNA, 10% (w/v) dextran sulfate, 1x Denhardt’s solution. For Xenopus, a shroom3
(Lee et al., 2009) digoxygenin-labelled antisense RNA probe and a pax2 (Heller &
Brändli, 1997) digoxygenin-labelled antisense RNA probe were used. For the mouse
kidney in situ hybridizations, a digoxygenin-labelled antisense RNA probe recognizing
the long version of Shroom3 (Hildebrand & Soriano, 1999) was used. To visualize the
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bound antisense probe, BM Purple (Roche) was used as the alkaline phosphatase
substrate. Following staining, embryos were fixed in MEMPFA followed by a bleaching
solution (1% hydrogen peroxide, 50% formamide, 0.5% SSC) to remove endogenous
pigmentation allowing for easier visualization of the staining. Embryos were visualized
via a Leica MZ12 dissecting microscope and images were captured using Northern
Eclipse Software (Empix Imaging; Mississauga, ON, Canada).

2.8 Paraffin sectioning
Prior to paraffin embedding, mouse kidneys were fixed with 4% PFA for 2 hours at room
temperature or overnight at 4°C. For embryos, the kidneys were fixed with the rest of the
embryo and the kidneys were subsequently separated from the other organs. Based on
Zeller (2001), embryos were first dehydrated with graded ethanols: 20 minutes in 70%,
20 minutes in 80%, and 2 steps in 100% for 20 minutes each. The samples were then
cleared in 2 steps of xylene for 20 minutes then 10 minutes. The next steps were done at
65°C. The samples were submerged in xylene:paraffin (1:1) for 1 hour then into fresh
pure paraffin wax (for 45 minutes or longer depending on the thickness of the sample). A
last solution change into a new fresh wax was performed and the embryos were placed
into their embedding molds, oriented (to allow for sagittal sections) and allowed to
infiltrate for 30 minutes at 65°C to prevent differential cooling of the sample. The
samples were then removed from the 65°C incubator and allowed to cool at room
temperature.
For paraffin slides of X-gal stained kidneys, kidneys were initially whole-mount X-gal
stained then paraffin embedded as described above. Sections were cut longitudinally at
10µm thickness to visualize the stain.
All paraffin slides were mounted onto SuperFrost Plus microscope slides (VWR) with a
coating of albumin:glycerin (1:1). Slides were covered in water and allowed to dry
overnight on a 37°C slide warmer. For the X-gal stained kidney slides, 3 xylene washes
of 5 minutes each were performed for removal of paraffin.
For the glomerular counts, sagittal sections were cut at a thickness of 7µm. Sequential
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sections were staggered across 5 slides such that each 7th section would be on a slide.
This would allow each slide to contain each glomerulus only once for counting purposes
based on the size of the glomeruli (Cebrián et al., 2004). For E18.5 counts, slides were
H&E stained using the standard CAT hematoxylin & Eosin Y procedure to visualize
glomeruli. All paraffin slides were coverslipped and sealed using Permount Mounting
Medium (Thermo Scientific).
Images of all paraffin slides were taken using a DAS Mikroskop Leitz DMRB highpower microscope and imaged by Image ProPlus. In order to perform glomerular counts,
images of each kidney section were taken. Counts were performed on one kidney each.
ImageJ was used to help count the glomeruli on each section and totals were calculated.

2.9 Immunofluorescence
Immunofluorescence studies were done on cryosections. Embryos and adult kidneys were
fixed in 4% PFA for up to 24 hours at 4°C. After fixation and prior to embedding,
embryonic kidneys were removed from the other organs. All kidneys were saturated in
30% sucrose in PBS at 4°C overnight and embedded the next day in Cryomatrix (Fisher
Scientific). Samples were frozen at -20°C and serial sections of 10µm were cut using a
Leica 3050 S motorized cryostat. The sections were mounted onto SuperFrost Plus
microscope slides (VWR) and dried on a 45°C warmer for up to 1 hour. Slides were
stored at -80°C until use for immunofluorescence.
The immunofluorescence protocol for cryosections was according to Fagotto and Brown
(2008) with the exception of the 0.2% Eriochrome black step. Actin immunofluorescence
was visualized using Oregon Green Phalloidin 488 conjugate (5µg/mL; Invitrogen).
Primary antibodies used were: a mouse monoclonal to ROCK1 (10 µg/mL; Abcam), and
a rabbit polyclonal to myosin light chain phosphorylated serine 20 (2.5µg/mL; Abcam).
The secondary antibodies used for the detection of the primary antibodies were Alexa
fluor 594 goat anti-rabbit (1:250) and Alexa fluor 488 goat anti-mouse IgG (1:250)
antibodies (Invitrogen molecular probes). As a negative control, slides were incubated
without primary antibody, but with secondary antibody to detect non-specific binding of
the secondary antibody. Slides were coverslipped with PermaFluor Aqueous Mounting
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Medium (Thermo Scientific) and stored at 4°C. Slides were visualized by confocal
microscopy using the Nikon A1R Confocal Microscope and images were taken using the
FV-10 ASW program.

2.10 Calculation of percentages of podocytes lacking cortical
localization of actin, ROCK1 or pMLC
Confocal images of 6-12 glomeruli from each embryo were collected from the actin
immunofluorescence slides and ROCK1, pMLC co-stained slides. The total number of
podocytes found across the different glomeruli of the embryo were counted and the
number of podocytes lacking cortical actin, ROCK1 or pMLC were also counted.
Percentages of podocytes lacking apical localization of subsequent protein were
calculated for each individual embryo. The percentage of podocytes lacking apical actin,
ROCK1 or pMLC were calculated as the number of podocytes lacking cortical
localization of the corresponding protein divided by the total number of podocytes
counted for that embryo.

2.11 Urine collection and analysis
For urine collection, male mice between 3 months to 1 year 3 months were scruffed and
pressure was applied to the bladder to initiate urination. Urine was collected on parafilm
and stored at -80°C. Urinalysis for proteinuria was performed using ChemStrip10 dip
sticks (Roche). Subsequently, the remaining urine samples were sent to our collaborators
who ran the urine on a polyacrylamide gel and performed a Coomassie Blue stain to test
for albumin in the urine.

2.12 Statistical analyses
To assess statistical significance for E18.5 glomerular counts and to compare the percent
of podocytes lacking apical actin, ROCK1 or pMLC at E13.5, E16.5 and E18.5, a oneway ANOVA was performed with a post-hoc Tukey’s test. The significance was set at p
< 0.05. To assess statistical difference between percent of podocytes lacking apical actin,
ROCK1 or pMLC at 3 months, an unpaired two-tailed t-test was performed with a
significance of p < 0.05. All statistics were performed using GraphPad Prism 6.0.
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Chapter 3

3

Results

3.1 Characterization of Shroom3 gene trap mice
The Shroom3Gt/Gt mice were backcrossed to C57BL/6 by Jackson Laboratory in order to
make them congenic with that strain. To ensure that this did not change the phenotype, I
compared the phenotype of the mice obtained from Jackson Laboratories to the
phenotype described for the original gene trap as characterized by Hildebrand & Soriano
(1999). I examined the phenotype of embryos at varying time points for organ defects.
There was 100% penetrant exencephaly in the Shroom3Gt/Gt embryos (Figure 8) as found
by Hildebrand & Soriano (1999). The exencephaly can be distinguished starting at E9.5
(Hildebrand & Soriano, 1999). The exencephaly was seen as the brain mushrooming out
of the skull. Some Shroom3Gt/Gt embryos also displayed other organ defects such as
herniation, but these phenotypes were not 100% penetrant as was described in the
original characterization. The Shroom3+/+ and Shroom3+/Gt embryos, on the other hand,
showed apparently normal development. In the original characterization, an 8%
penetrance of a less severe form of exencephaly was noted in Shroom3+/Gt embryos. Upon
my own characterization of the congenic C57BL/6 mice, few Shroom3+/Gt embryos also
displayed a less severe exencephaly, but at a lower frequency than that characterized
(Hildebrand & Soriano, 1999). Thus, the generation of the congenic Shroom3Gt/Gt mice
had only minor differences from the mutant mice as originally described by Hildebrand
& Soriano (1999). This validates my use of the gene trap for my research on loss of
Shroom3 function, both heterozygous and homozygous.
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Shroom3+/+'

Shroom3+/Gt'

Shroom3Gt/Gt'

Figure 8. Shroom3Gt/Gt mice have 100% penetrant exencephaly. To verify the gene
trap phenotype on a congenic C57BL/6 background, exencephaly was examined. For
Shroom3Gt/Gt mice, there was 100% penetrant exencephaly (black arrow). Exencephaly is
seen as the brain “mushrooming” out of the skull. Due to the exencephaly, Shroom3Gt/Gt
mice are perinatal lethal. Shroom3+/+ and Shroom3+/Gt mice appear normal and live into
adulthood. Images are of E16.5 embryos.
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3.2 Shroom3 expression in mouse embryonic kidney
Although it is known that Shroom3 is expressed in adult human and Xenopus kidneys,
there is limited information on Shroom3 expression in the mouse kidney. All that is
currently known is that Shroom3 is expressed in the tubules of the adult mouse kidney
(Menon et al., 2015). Because the gene trap model I used inserts lacZ between exon 3 and
4 of Shroom3, β-galactosidase is produced under the endogenous Shroom3 promoter. Xgal stain reacts with β-galactosidase and can act as a reporter of where Shroom3 is
expressed by a blue precipitate. To examine metanephros expression of Shroom3, I
stained kidneys beginning from E11.5 when metanephric development initiates. I first
detected Shroom3 expression at E11.5 and found expression throughout the rest of mouse
kidney embryonic development (Figure 9; N=3-8 for each age group). Shroom3 is
expressed within specific cell types of the kidney. Shroom3 is expressed in the cap
mesenchyme (Figure 9, 10, 11, 12). Shroom3 is also expressed in the collecting ducts,
but the expression does not appear until E16.5 and onwards (Figure 10, 12, 13). Lastly
and most importantly to the focus of my project, Shroom3 is expressed in the podocytes
(Figure 10, 12).
To verify that the X-gal staining accurately recapitulates endogenous Shroom3
expression, I performed in situ hybridization using a mouse Shroom3 probe (Figure 13;
N=3-5 for each age group). I found that the in situ hybridization recapitulated the X-gal
staining in that Shroom3 expression is within the cap mesenchyme, in the collecting ducts
starting at E16.5 and cells within the cortex. Although in situ hybridization shows similar
staining as the X-gal staining, the X-gal staining gives significantly clearer images of
Shroom3 expression. In addition, using an antibody against Shroom3, our collaborators
also verified that mRNA predicts Shroom3 protein presence in the same cell types.
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Figure 9. Shroom3 expression is seen throughout metanephric development.
Shroom3 is expressed during embryonic metanephric development from E11.5 to E18.5
as determined by X-gal staining (blue stain). The cap mesenchyme staining is seen as the
outer blue staining of the kidneys at all time points. Thus, Shroom3 is expressed
throughout nephrogenesis of the metanephric kidney.
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Figure 10. Shroom3 is expressed in the cap mesenchyme, the podocytes, and the
collecting ducts during embryonic development. Shroom3 expression is seen in the cap
mesenchyme (red arrow), the collecting ducts (yellow arrow), and the podocytes (black
arrow). The cap mesenchyme is seen as the outer blue rim. The podocytes are seen as
circular rings in the cortex around the glomeruli and the collecting ducts are seen in the
medullary region of the kidney.
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Figure 11. Shroom3 expression in the cap mesenchyme at E16.5. Kidneys were X-gal
stained to view Shroom3 expression. The cap mesenchyme is seen as the blue outer
cortex staining of the kidney. The cap mesenchyme staining appears as commas or
horseshoes throughout the surface of the kidney.

45

Figure 12. Sections of X-gal stained embryonic kidneys demonstrating expression of
Shroom3 in the podocytes, collecting ducts, and cap mesenchyme. Sections of X-gal
stained kidneys for Shroom3 expression were visualized. Shroom3 is expressed in the
podocytes (black arrows), the collecting ducts (green arrow), and the cap mesenchyme
(red arrow). The podocytes are seen as rings surrounding the glomerulus. The sections
are from an E16.5 Shroom3+/Gt embryo. Scale bar is 20 µm.
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Figure 13. In situ hybridization using a mouse Shroom3 probe largely recapitulates
X-gal staining for Shroom3 expression. To verify that the X-gal Shroom3 staining is
accurate, in situ hybridization using an antisense mRNA probe against mouse Shroom3
was used. In situ hybridization shows that there is Shroom3 expression in the collecting
ducts beginning at E16.5 (black arrow) and that there is cap mesenchyme staining as well
as staining of cell types in the cortex. Thus, in situ hybridization verifies that X-gal
staining recapitulates endogenous Shroom3 expression.
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3.3 Shroom3 expression in mouse adult kidney
To test if Shroom3 is expressed in the adult kidney I performed X-gal staining on adult
kidneys. Shroom3+/Gt kidneys were analyzed because Shroom3Gt/Gt mice die at birth due
to exencephaly. Staining of Shroom3+/+ mice was used as a control as they would be
predicted to show absence of staining. I found expression of Shroom3 is maintained even
after the kidney has fully matured and has completed nephrogenesis (Figure 14, 15; N=26
for each genotype). Shroom3 is still expressed within the podocytes, and collecting ducts
at 1-3 months (Figure 15; N=3 for X-gal sections). The cap mesenchyme is no longer
present thus there is no staining for this cell type. Unlike in the embryonic kidneys, I see
relatively strong staining of the tubules in the adult kidney (Figure 15). Furthermore,
Shroom3 is expressed in the adult ureter (Figure 14).
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Figure 14. Shroom3 expression in the adult kidney by X-gal visualization of
Shroom3+/Gt kidneys. To verify that the X-gal staining is specific for the gene trap, wildtype counterparts (Shroom3+/+) were stained simultaneously and show the expected
absence of staining (bottom images). Whole-mount X-gal staining shows that Shroom3 is
expressed in the collecting ducts, tubules and glomeruli but also in cells of the ureter
(white arrow). Images are of 2-month-old male kidneys. Shroom3+/Gt kidneys are not
considerably smaller than Shroom3+/+ kidneys.
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Figure 15. Shroom3 is expressed in the collecting ducts, the tubules, and the
podocytes of the adult mouse kidney. Kidneys were halved and X-gal stained (A, B)
with subsequent visualization on paraffin slides (C). In the adult kidney, there is
expression of Shroom3 in the collecting ducts (red arrow) and the podocytes of the
glomerulus (black arrow), which is similar to embryonic kidneys. Unlike the embryonic
kidneys, there is no staining of the cap mesenchyme as it is no longer present. However,
there is relatively strong staining for the tubules (yellow arrow), which was not seen in
embryonic kidneys. Scale bar is 20 µm.
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3.4 Evolutionary conservation of Shroom3 kidney
expression
To test the evolutionary conservation of Shroom3 expression in kidney structures and to
elucidate on the role of Shroom3, at least in lower vertebrates, I confirmed Xenopus
laevis pronephros Shroom3 expression (Lee et al., 2009). Shroom3 expression is also
found in the zebrafish pronephros (Yeo et al., 2015). In addition, to examining the
pronephros, I assessed the mesonephros of Xenopus which has never been examined.
Staining of the mesonephros would be more analogous to staining of the metanephros in
higher vertebrates, including mammals. However, the pronephros is still of interest
because aquatic animals require regulation of water balance. Thus, the pronephros is not
merely a transient structure; it is fully functional (Wessely & Tran, 2011).
In Xenopus, the pronephros begins to develop at stage 28 (Nieuwkoop & Faber, 1994).
To examine pronephros shroom3 expression, I looked at stage 33/34 embryos (N=15-20).
To help visualize the location of the pronephros in Xenopus, I used an antisense diglabeled probe against Xenopus pax2. Pax2 encodes a transcription factor required in the
cap mesenchyme for epithelial transition (Harshman & Brophy, 2012). In mammals,
Pax2 is required for normal metanephric development. In Xenopus, pax2 is required for
the terminal differentiation of the pronephric tubule and thus expression can be seen
along the pronephros (Buisson et al., 2015). Pax2 is also required for maintenance and
full development of the mesonephros of Xenopus. Using a shroom3 antisense dig-labeled
RNA probe at stage 33/34, there is faint, but specific staining for shroom3 in the
pronephros (Figure 16). Since Shroom3 is expressed in mammals and lower vertebrates,
it suggests an evolutionary conserved role for Shroom3 in the kidney.
Mesonephros development initiates at stage 39 in Xenopus and is the final form of the
kidney (Nieuwkoop & Faber, 1994). To visualize whether the mesonephros expresses
shroom3, embryos at stage 48 were fixed and in situ hybridization was performed for
shroom3 expression. Again as a positive control for staining of the mesonephros, a pax2
probe was also used (Figure 16; N=10-15). Unlike the pronephros, I could not detect
shroom3 expression in the mesonephros suggesting that, in Xenopus, shroom3 may not
play a role in the mature mesonephric kidney.
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Figure 16. Shroom3 expression could be detected in the pronephros, but not the
mesonephros, of later Xenopus embryos. To visualize structure and location of the
pronephros and mesonephros, a pax2 probe was used. Pax2 is expressed throughout
kidney development. At stage 33/34, the pronephros (black arrow) shows faint, but
specific staining for shroom3 expression. At stage 48, the mesonephros is present (red
arrow), but there is no detectable shroom3 expression in the mesonephros. At stage 48 the
heads of the embryos were removed by razor blades to reduce non-specific cavity
staining.
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3.5 Loss of Shroom3 results in glomerular defects
Since I demonstrated that Shroom3 is expressed throughout mouse kidney development, I
next wanted to test my hypothesis that it is important in kidney development and
function. I compared the kidneys of Shroom3 heterozygous and homozygous mutants
with wild-type mice. Loss of Shroom3, in both Shroom3+/Gt and Shroom3Gt/Gt mice,
resulted in glomerular cysts (Figure 17). Our collaborators verified the presence of these
glomerular cysts in Shroom3+/Gt and Shroom3Gt/Gt with a pathologist. Further work done
by our collaborators showed that they see few glomerular cysts from E18.5 and onwards.
Therefore, I hypothesized that the cystic glomeruli disappear and that this would result in
a decreased glomerular number (otherwise referred to as nephron number). There is
evidence that glomerular cysts can reduce nephron number (Gibson et al., 1996). In order
to show a reduction in nephron number, I performed glomerular counts on single kidneys
from individual embryos. The glomerular number was compared between heterozygous
and homozygous Shroom3 mutant and wild-type mice. Homozygotes for the gene trap
are perinatal lethal so in order to examine all 3 genotypes, I chose to do glomerular
counts at E18.5. From the counts at E18.5, I found that with loss of Shroom3 expression,
there was a reduction in nephron number (Figure 18; N=5 for Shroom3+/+ and
Shroom3Gt/Gt, N=7 for Shroom3+/Gt). In Shroom3+/Gt, there is a significant decrease in
glomerular number from Shroom3+/+ (p=0.0067). Importantly, in Shroom3Gt/Gt there is a
further significant decrease in glomerular number as compared to both Shroom3+/+
(p=0.0001) and Shroom3+/Gt (p=0.0416). Therefore, loss of Shroom3 results in a decrease
in glomerular number in a dose-dependent manner.
Shroom3Gt/Gt mice are perinatal lethal, most likely due to the severe exencephaly
(Hildebrand & Soriano, 1999). Shroom3+/Gt on the other hand, normally survive into
adulthood as there is still functional Shroom3 present to allow for proper neural tube
closure. Although Shroom3+/Gt mice can live normally into adulthood, they have a
reduction in nephron number compared to Shroom3+/+. Thus, Shroom3+/Gt may appear
normal and healthy, but they may be predisposed to CKD or hypertension as suggested
by a reduction in nephron endowment. Since there are glomerular defects and decreased
glomerular number, I sought to determine what functional consequences may occur in
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Shroom3+/Gt adult mice and what potential mechanism may result in these glomerular
defects.
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Figure 17. Loss of Shroom3 results in glomerular cysts. Shroom3+/+ mice show normal
glomeruli with a non-expanded Bowman’s capsule. In Shroom3+/Gt and Shroom3Gt/Gt
mice, the full to partial loss of Shroom3 results in glomerular cysts as seen in the
enlarged images of the glomeruli of Shroom3+/Gt and Shroom3Gt/Gt. Glomerular cysts are
defined as dilation of the Bowman’s capsule. Sections are of E18.5 kidneys. Scale bars
represent 100 µm.

55

Figure 18. Glomerular counts reveal that loss of Shroom3 results in a reduction in
the number of nephrons. Because there are few to no glomerular cysts present in
Shroom3+/Gt and Shroom3Gt/Gt kidneys at later time points, I hypothesize that they are lost
from the histology and lower nephron number. Counts were performed on single kidneys
of embryos at E18.5 (N=5 for Shroom3+/+ and Shroom3Gt/Gt and N=7 for Shroom3+/Gt).
There is a significant decrease in the number of glomeruli in Shroom3+/Gt kidneys
compared to Shroom3+/+ kidneys (p=0.0067). There is also a significant reduction in the
number of glomeruli in Shroom3Gt/Gt kidneys compared to Shroom3+/+ (p=0.0001).
Lastly, there is a significant decrease in the number of glomeruli in Shroom3Gt/Gt
compared to Shroom3+/Gt (p=0.0416). There is a dose-dependent reduction in the number
of glomeruli with loss of Shroom3. Data was analyzed using a one-way ANOVA with a
Tukey’s post-hoc test. Error bars represent the standard error of the means.
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3.6 Examination of actin in podocytes
Regulation of the actin cytoskeleton is very important to the function of podocytes.
Therefore, I sought to determine whether Shroom3 loss affected the actin cytoskeleton
organization in podocytes (N=6-12 glomeruli per embryo and N=3 embryos per genotype
at each age group). Before looking at mechanism that may lead to disruptions in actin
organization, such as disruptions in the actions of ROCK and pMLC, I first examined
whether there were differences in actin localization. Important to note, all
immunofluorescence images have autofluorescence of the nuclei. I found that, in
Shroom3+/+ kidneys of age groups E13.5, E16.5, E18.5 and 3 months of age, that the vast
majority showed normal cortical localization of actin within the podocytes (Figure 19). In
Shroom3+/Gt and Shroom3Gt/Gt, however, I noticed that in some podocytes there was loss
of apical localization of actin. Loss of apical localization of actin was seen in both
Shroom3+/Gt and Shroom3Gt/Gt at all time points with the exception of E13.5 Shroom3+/Gt.
To verify that there is a difference in the number of podocytes lacking apical actin, I
calculated the percentages of podocytes lacking apical actin in each embryo (N=6-12
glomeruli per embryo and N=3 embryos per genotype with N=47-100 podocytes per
embryo). Shroom3+/+ podocytes almost never lack apical actin. There was no significant
difference between the three genotypes in terms of the percent of podocytes lacking
apical actin at E13.5, E16.5 and E18.5 (Figure 20). However, for the 3 month-old mice,
there is a significant increase in the percentage of podocytes lacking apical actin in the
Shroom3+/Gt mice compared to Shroom3+/+ (p=0.0159). Thus, in adults there is the
potential for defects in some podocytes due to impaired actin localization with loss of
Shroom3, which may result in functional consequences.
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Figure 19. Cortical actin expression is lost in some podocytes with loss of Shroom3.
Shroom3 is expressed within the podocytes, which are a specialized epithelial cell. In
Shroom3+/+ mice, there is apical localization of actin in the podocytes (white arrows).
With loss of Shroom3, some podocytes in both Shroom3+/Gt and Shroom3Gt/Gt mice lack
apical localization of actin (white arrows). Thus, it seems that the podocytes are another
type of epithelial cell that require Shroom3 for apical localization of actin. Scale bars
represent 10 µm.
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Figure 20. Increase in the percentage of podocytes lacking apical actin in
Shroom3+/Gt 3-month-old mice. Shroom3+/+ podocytes rarely lack apical actin. At E13.5,
E16.5 and E18.5, there is no statistical difference in the podocytes lacking apical actin
between the 3 genotypes. At 3 months, Shroom3+/Gt kidneys show a significant increase
in the percentage of podocytes lacking apical actin compared to Shroom3+/+ (p=0.0159).
This suggests that Shroom3 loss results in loss of apical localization of actin in some
podocytes which could result in disorganization of the podocyte actin cytoskeleton. For
E13.5, E16.5 and E18.5, data was analyzed using a one-way ANOVA with a Tukey’s
post-hoc test (N=3 for each genotype at each time point). For 3 months of age, an
unpaired two-tailed t-test was performed. Error bars represent the standard error of the
means.
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3.7 Examination of downstream effectors of Shroom3 that
act on the actin cytoskeleton
Since I observed disorganization of the actin cytoskeleton, to elucidate the mechanism for
this loss of actin localization, I examined known downstream effectors of Shroom3 that
act on the actin cytoskeleton, ROCK1 and pMLC, to determine if they are mislocalized. I
performed ROCK1 (Figure 21) and pMLC (Figure 22) immunofluorescence to examine
localization of these proteins (N=6-12 glomeruli per embryo and N=3 embryos per
genotype at each age group). I noticed a similar pattern to the loss of actin localization
for ROCK1 and pMLC. With loss of Shroom3, heterozygous and homozygous, there is
loss of apical localization of ROCK1 and pMLC within some podocytes at all time points
(E13.5, E16.5, E18.5 and 3 months). Note that kidneys were double stained for ROCK1
and pMLC using different fluorophores and so although some images show the same
region of kidney, they are detecting the different proteins. This mislocalization of
ROCK1 and pMLC provides a potential mechanism by which loss of Shroom3 function
may result in loss of apical actin localization and subsequent podocyte defects.
In order to quantify the defects in cortical localization of ROCK1 and pMLC, as done for
actin localization, in Shroom3+/Gt and Shroom3Gt/Gt embryos and 3-month-old mice, I
counted the number of podocytes showing abnormal localization (N=6-12 glomeruli per
embryo, N=21-81 podocytes per embryo, and N=3 embryos per genotype at each age
group). There was a significant increase in the percent of podocytes lacking both apical
ROCK1 (Figure 23; p=0.0308) and pMLC (Figure 24; p=0.0321) in Shroom3Gt/Gt E13.5
embryos compared to Shroom3+/+. However, there was no significant difference in the
percentage of podocytes showing mislocalized ROCK1 or pMLC at any of the other time
points. Shroom3+/Gt 3-month-old mice did not reach significance with respect to an
increase in the percent of podocytes lacking apical ROCK1 or pMLC as seen with loss of
apical actin. Thus, loss of Shroom3 can potentially result in loss of apical ROCK1 and
pMLC in podocytes.
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Figure 21. Apical ROCK1 expression is lost in some podocytes of Shroom3+/Gt and
Shroom3Gt/Gt mice. Shroom3 and ROCK1 are expressed within podocytes. A vast
majority of podocytes in Shroom3+/+ mice have cortical localization of ROCK1 (white
arrows). With loss of Shroom3, some podocytes in both Shroom3+/Gt and Shroom3Gt/Gt
mice lack apical localization of ROCK1 (white arrows). Thus, Shroom3 appears to be
required in podocytes to cause apical localization of ROCK1 and loss of Shroom3 can
result in mislocalization of ROCK1 in some podocytes. The scale bar represents 10 µm.
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Figure 22. Cortical pMLC expression is lost in some podocytes of Shroom3+/Gt and
Shroom3Gt/Gt mice. Shroom3 and pMLC are expressed in the podocytes. In Shroom3+/+
kidneys, the vast majority of podocytes show localization of pMLC to the apical surface
(white arrows). With loss of Shroom3, some podocytes in both Shroom3+/Gt and
Shroom3Gt/Gt mice lack apical localization of pMLC (white arrows). Thus, it appears
Shroom3 is required in podocytes, a specialized epithelial cell, for phosphorylation of
MLC at the apical surface. The scale bars represent 10 µm.
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Figure 23. There is an increase in the percent of podocytes lacking apical ROCK1 in
Shroom3Gt/Gt E13.5 embryos. Shroom3 and ROCK1 are expressed in podocytes. There
is a significant increase in the percentage of podocytes lacking cortical localization of
ROCK1 at E13.5 in Shroom3Gt/Gt embryos compared to Shroom3+/+ (p=0.0308). No
significance is reached at other age groups or for other genotypes with respect to loss of
apical localization of ROCK1. For E13.5, E16.5 and E18.5, the data was analyzed using a
one-way ANOVA with a Tukey’s post-hoc test (N=3 for each genotype at each time
point). For 3 months of age, data was analyzed using an unpaired two-tailed t-test. Error
bars represent the standard error of the means.
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E13.5'

E16.5'

E18.5'

3'months'

Figure 24. There is an increase in the percentage of podocytes lacking apical pMLC
in Shroom3Gt/Gt at E13.5. Shroom3 and pMLC are both expressed in podocytes. There is
a significant increase in the percentage of podocytes lacking cortical localization of
pMLC in Shroom3Gt/Gt embryos at E13.5 compared to Shroom3+/+ (p=0.03021). However,
no significance is reached at other age groups or for other genotypes with respect to loss
of apical localization of pMLC. For E13.5, E16.5 and E18.5, the data was analyzed using
a one-way ANOVA with a Tukey’s post-hoc test. For 3 months of age, data was analyzed
using an unpaired two-tailed t-test. Error bars represent the standard error of the means.
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3.8 Functional consequences of the loss of Shroom3
The pattern seen for loss of ROCK1, pMLC and actin localization to the apical surface is
only seen in some podocytes of both Shroom3+/Gt and Shroom3Gt/Gt. The glomeruli that
show these defective podocytes may be the ones that are lost and decrease nephron
number. Because I still see defective podocytes for cortical actin localization at 3 months
of age in Shroom3+/Gt mice, I predicted that there would be functional consequences in
adulthood.

3.8.1

Proteinuria

Shroom3+/Gt mice can live normally into adulthood like their wild-type counterparts, but
they appear to have podocyte and glomerular defects as evidenced by reduced nephron
number and loss of apical actin in some podocytes. Thus, I predicted that there would be
functional consequences due to these defects. Homozygous mice for the gene trap could
not be assessed as they are perinatal lethal. A key hallmark of kidney impairment is
protein found in the urine, otherwise known as proteinuria. A key protein that can be
detected in proteinuria is albumin, hence this condition is called albuminuria. Typically,
very little albumin should be found in the urine as it is a high molecular weight plasma
protein that is not generally filtered by the glomerulus and thus albumin remains in the
blood. I collected urine from mice 3 months of age up to 1 year 3 months of age (N=30
for each group) and tested the presence of protein in the urine using protein dipsticks.
Mice were aged to approximately 1 year to represent middle age to determine if
dysfunction begins later in life as is common with CKD. In 3-month-old males, I saw no
indication of increased protein in the urine in either Shroom3+/+ or Shroom3+/Gt mice. For
males between 10 months and 1 year 3 months of age, 4 out of 30 Shroom3+/Gt adult mice
showed higher levels of protein in the urine compared to 0 out of 30 of their wild-type
counterparts. My urine samples were sent to our collaborators and the urine was run on a
polyacrylamide gel with a Coomassie Blue stain (Figure 25). Corresponding Shroom3+/Gt
with higher levels of proteinuria indicated by the dipsticks were shown to have increased
albumin in the urine. A positive albumin control was run to show the typical size of
albumin at 70kDa.
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Shroom3+/+ Shroom3+/+ Shroom3+/+ Shroom3+/Gt Shroom3+/Gt Shroom3+/Gt

70 kDa
70kDa

Figure 25. Coomassie Blue stain reveals increased albumin in the urine of
Shroom3+/Gt 1-year-old mice. Urine samples were run on a polyacrylamide gel then
stained using Coomassie Blue. Staining reveals albumin in the urine of some Shroom3+/Gt
1-year old male mice. Shroom3+/+ 1-year-old males do not show staining of albumin.
Albumin was run as a positive control in the first lane to confirm that the observed band
at 70kDa was albumin.
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3.9 Potential effects of loss of Shroom3 on amniotic fluid
Generally it is easy to tell which embryos are Shroom3Gt/Gt mice as their amniotic sacs
have a noticeable bloodiness of the amniotic fluid, which is potentially attributable to the
exencephaly whereby blood leaks into the amniotic fluid due to the tissue damage (N=510 embryos each at E16.5, E17.5 and E18.5). However, there is also increased swelling
that suggests a greater amount of amniotic fluid, which may in part be caused by kidney
dysfunction (Figure 26). Amniotic fluid volume is maintained by fetal urination and fetal
lung fluid secretion countered by fetal swallowing and intramembranous absorption
(Cheung & Brace, 2005). If the filtration barriers of the kidneys are compromised, it may
be resulting in a greater amount of urination and loss of protein in the urine and thus a
greater amount of amniotic fluid.
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Shroom3+/+'

Shroom3+/Gt'

Shroom3Gt/Gt'

Figure . Mice homozygous for the gene trap have a greater amount of amniotic fluid
compared to Shroom3+/+ and Shroom3+/Gt. Shroom3Gt/Gt mice have bloody amniotic
fluid which is most likely caused by the 100% penetrant exencephaly. This is unlike
Shroom3+/+ mice and Shroom3+/Gt mice who have clear amniotic fluids. However,
Shroom3Gt/Gt embryos also have a greater volume of amniotic fluid compared to
Shroom3+/+ and Shroom3+/Gt mice. Although part of the increase in amniotic fluid may be
a result of the exencephaly, kidney dysfunction and increased urination into the amniotic
fluid may also be a contributor. The images are of E17.5 embryos prior to being removed
from the placenta to allow visualization of amniotic sacs.
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3.10 PolyPhen-2 predictions of potential SNPs in SHROOM3
that are deleterious in the human population
The National Heart, Lung and Blood Institute (NHLBI) Exome Sequencing Project (ESP)
was initiated to discover novel genes and mechanisms that may contribute to heart, lung
and blood disorders. The ESP employs next generation sequencing of protein coding
sequences and provides a large dataset of actual genomes of individuals. Thus, the SNPs
that are listed exist within the population. The dataset includes 200,000 individuals across
the United States. One key tool that is given is a prediction as to whether the SNP is
deleterious or most likely benign based on PolyPhen-2 (Polymorphism Phenotyping
version 2). PolyPhen-2 analyzes amino acid substitutions and predicts whether a SNP in a
protein is benign, possibly damaging or probably damaging based on physical and
comparative considerations.
I compiled a list of all the SNPs in SHROOM3 listed in the NHLBI ESP that are
predicted to be probably damaging by PolyPhen-2 within the population sampled (Table
3). These predictions are based on potential alterations to the protein structure and
stability. Future work will need to be performed to determine whether these SNPs are
deleterious as predicted by the program. These potentially damaging SNPs may represent
hypomorphs, which would be analogous to Shroom3+/Gt adult mice. Interesting to note is
that all these SNPs result in a missense mutation, yet they are predicted to be damaging to
SHROOM3 function. This is similar to the mutant mice that contain a SNP in exon 9
causing the same phenotype as the gene trap when homozygous.
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Table 3. Existing SNPs in SHROOM3 with a probably damaging PolyPhen-2
prediction. The National Heart, Lung, and Blood Institute performed whole exome
sequencing analysis of over 200,000 individuals from the United States from a number of
different studies. These SNPs are found within the population and were predicted by
PolyPhen-2 that they would be probably damaging to the function of SHROOM3. The
less common SNP is found on the left and the more common SNP is found on the right.
The amino acid listed first is the amino acid that the less common SNP encodes whereas
the second amino acid is the amino acid encoded by the general SNP. These alleles may
be evidence of hypomorphic SHROOM3 alleles.
Amino

Variant

Allele

Allele

Acid

Allele

Frequency

Frequency Acid

Position

Amino

(%)

Change

Protein

Domain

Change

Location

32

C/T

C=1/T=13005

7.69x10-3

Pro, Leu

Missense

/

35

T/G

T=1/G=13005

7.69x10-3

Val, Gly

Missense

PDZ

60

C/G

C=2/G=13004

1.54x10-2

Arg, Gly

Missense

PDZ

60

T/G

T=34/G=12972

0.261

Gly, Val

Missense

PDZ

80

T/A

T=2/A=13004

1.54x10-2

Tyr, Asn

Missense

PDZ

99

C/A

C=1/A=13005

7.69x10-3

Ser, Tyr

Missense

PDZ

106

C/G

C=15/G=12991

0.115

Lys, Val

Missense

PDZ

107

A/G

A=2, G=13004

1.54x10-2

Arg, His

Missense

PDZ

147

A/T

A=1891/T=11115

17.5

His, Lys

Missense

/

181

T/C

T=1/C=13005

7.69x10-3

Phe, Ser

Missense

/

193

C/A

C=1/A=13005

7.69x10-3

Ser, Tyr

Missense

/

207

T/C

T=27/C=12979

0.208

Tyr, His

Missense

/
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Amino

Variant

Allele

Allele

Acid

Allele

Frequency

Frequency Acid

Position

Amino

(%)

Change

Protein

Domain

Change

Location

209

G/A

G=2/A=13004

1.54x10-2

Cys, Tyr

Missense

/

246

C/T

C=1/T=13005

7.69x10-3

Thr, Ile

Missense

/

292

A/G

A=1/G=13005

7.69x10-3

Gln, Arg

Missense

/

352

A/G

A=15/G=12991

0.115

Gln, Arg

Missense

/

363

G/A

G=1/A=13005

7.69x10-3

Arg, Gln

Missense

/

367

G/T

G=20/T=12986

0.154

Arg, Ser

Missense

/

388

T/C

T=1/C=13005

7.69x10-3

Trp, Arg

Missense

/

389

A/T

A=3/T=13003

2.31x10-2

Arg, Ser

Missense

/

411

T/C

T=1/C=13005

7.69x10-3

Trp, Tyr

Missense

/

469

G/C

G=7225/C=5781

55.6

Arg, Phe

Missense

/

517

C/A

C=1/A=13005

7.69x10-3

His, Asn

Missense

/

564

C/A

C=159/A=12847

1.22

Ala, Glu

Missense

/

601

T/C

T=8/C=12998

6.15 x10-2

Tyr, His

Missense

/

624

G/A

G=2/A=13004

1.54x10-2

Gly, Glu

Missense

/

668

C/T

C=1/T=13005

7.69x10-3

Thr, Ile

Missense

/

890

A/G

A=1/G=12725

7.86x10-3

Asn, Ser

Missense

ASD1

927

A/G

A=1/G=12705

7.87 x10-3

Asn, Ser

Missense

ASD1

945

T/A

T=1/A=12393

8.07x10-3

Val, Asp

Missense

ASD1
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Amino

Variant

Allele

Allele

Acid

Allele	
  

Frequency	
  

Frequency Acid

Position	
  

Amino

(%)	
  

Change	
  

Protein

Domain

Change	
  

Location	
  

1012

A/C

A=67/C=12581

0.530

Asn, Thr

Missense

ASD1

1058

A/G

A=1/G=12979

7.70x10-3

His, Arg

Missense

ASD1

1085

A/G

A=1/G=12899

7.75x10-3

Thr, Ala

Missense

/

1229

G/C

G=1/C=12961

7.71x10-3

Trp, Ser

Missense

/

1468

A/G

A=1/G=13005

7.69x10-3

Asn, Ser

Missense

/

1506

G/C

G=2/C=13004

1.54x10-2

Glu, Asp

Missense

/

1507

A/G

A=15/G=12991

0.115

Lys, Glu

Missense

/

1518

T/C

T=1/C=13005

7.69x10-3

Met, Thr

Missense

/

1764

C/A

C=2/A=13004

1.54x10-2

Gln, Lys

Missense

ASD2

1778

C/G

C=1/G=13005

7.69x10-3

His, Asp

Missense

ASD2

1780

G/A

G=1/A=13005

7.69x10-3

Ser, Asn

Missense

ASD2

1812

C/A

C=1/A=13005

7.69x10-3

Thr, Asn

Missense

ASD2

1836

A/G

A=1/G=13005

7.69x10-3

Ile, Met

Missense

ASD2

1857

T/C

T=1/C=13005

7.69x10-3

Cys, Arg

Missense

ASD2

1857

A/G

A=1/G=13005

7.69x10-3

His, Arg

Missense

ASD2

1864

A/G

A=7/G=12999

5.38x10-2

Asp, Gly

Missense

ASD2

1892

T/C

T=1/G=13005

7.69x10-3

Trp, Arg

Missense

ASD2

1892

A/G

A=1/G=13005

7.69x10-3

Gln, Arg

Missense

ASD2
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Amino

Variant

Allele

Allele

Acid

Allele	
  

Frequency	
  

Frequency Acid

Position	
  
1935

T/A

T=1/A=13005

Amino

(%)	
  

Change	
  

7.69x10-3

Lys, Gln

Protein

Domain

Change	
  

Location	
  

Missense

ASD2
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Chapter 4

4

Discussion

Chronic kidney disease is a major health burden affecting approximately 10% of the
population in industrialized nations and the rate is steadily increasing (Coresh et al.,
2007; Hallan et al., 2006; Zhang & Rothenbacher, 2008). With the prevalence of CKD
increasing in the population, it is important to understand what factors, both
environmental and genetic, that may predispose certain individuals to CKD. Although
hypertension and diabetes are the largest known risk factors for CKD (Fox et al., 2004a;
Lash et al., 2009), there is a definite genetic component to kidney disease (Bochud et al.,
2005; Fox et al., 2004b; Lancastor & Gleeson, 2010; Langefeld et al., 2004). Based on
my work, I propose to add Shroom3 as an important gene involved in kidney
development and function.

4.1 Shroom3 is expressed in the kidney during embryonic
development and adulthood
I have demonstrated that Shroom3 is expressed in the mouse kidney, which has not been
previously established other than in the adult kidney (Menon et al., 2015). Shroom3
expression is detected as early as E11.5 and is seen throughout embryonic metanephric
development (Figure 9) and adult life (Figure 14, 15). During embryonic development,
Shroom3 is expressed in the cap mesenchyme, podocytes, and collecting ducts (Figure
10, 11, 12). In adults, there is no expression of Shroom3 in the cap mesenchyme as this
structure no longer exists in a fully mature kidney. In the adult kidney, there is Shroom3
expression in the podocytes, collecting ducts and the tubules (Figure 14, 15). Although
recent papers have examined the role of Shroom3 in the kidney, my results are unique in
that I document Shroom3 expression throughout development of the mouse kidney.
Importantly, Shroom3 is expressed in mouse podocytes and there appears to be staining
of cells in the glomerulus of humans (Menon et al., 2015), suggesting that SHROOM3 is
also expressed in human podocytes. Expression in the podocytes provides a potential
explanation for many of the associations between SHROOM3 and kidney function in
humans if SHROOM3 plays a role in podocyte function.
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Shroom3 is not just expressed in mammalian kidneys but rather, Shroom3 expression
appears to be evolutionarily conserved in vertebrates as the Xenopus pronephros also
expresses Shroom3 (Figure 16; also verified by Lee et al., 2009). Shroom3 appears to be
important in early kidney development as Xenopus embryos express Shroom3 in the
pronephros, but does not appear to express Shroom3 in the mesonephros, the final stage
of Xenopus kidney. However, in mice and humans, Shroom3 is expressed in the last stage
of kidney development, the metanephros. This suggests that, in mammals, Shroom3 is
required for not just development of the kidney, but maintenance of function later in life.
In contrast, Shroom3 may be required for normal development, but not maintenance of
the kidney in lower vertebrates.

4.2 Shroom3 is necessary for normal glomerular
development
My analysis of Shroom3+/Gt and Shroom3Gt/Gt mice indicate that they suffer from kidney
defects as evidenced by glomerular cysts (Figure 17). If glomerular cysts are lost, it is
predicted to result in a decrease in glomerular number (Gibson et al., 1996) and this is
what appears to occur in the Shroom3 deficient mice as there is a dose-dependent
decrease in the number of glomeruli with loss of Shroom3 wild-type alleles (Figure 18).
Furthermore, our collaborators at McMaster University have also noticed the presence of
degenerating glomeruli within Shroom3+/Gt and Shroom3Gt/Gt E13.5 (Figure A1) and
E14.5 kidneys. These degenerating glomeruli also suggest that the cystic glomeruli are
likely lost. Of particular interest is that Shroom3+/Gt mice also have a significant decrease
in glomerular number compared to the Shroom3+/+ at E18.5. Nephron endowment refers
to the set number of nephrons that an individual has early in life and there is no increase
in that number after that point. A decreased glomerular number cannot be corrected in
later life (Brenner et al., 1988; Keller et al., 2003). Thus, even reduced, rather than just
complete loss, of Shroom3 expression can have detrimental effects. Since SHROOM3 is
expressed in human kidney, it is hoped that our mouse model may be useful in studying
the effects of hypomorphic SHROOM3 activity on kidney development and function. I
would predict that humans would not survive with a complete loss of SHROOM3
function since mice homozygous for loss of Shroom3 activity have 100% penetrant
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exencephaly. However, it is likely that there are humans with decreased SHROOM3
function who would be similar to my mouse model with a Shroom3+/Gt genotype. The
potential of the numerous identified mutations predicted to be probably damaging to
SHROOM3 in the human genome (Table 1) also suggest that there are likely to be
patients with reduced SHROOM3 activity.
Brachyrrhine (Br) mice have a semidominant mutation resulting in renal hypoplasia and
frontonasal dysplasia (Fogelgren et al., 2008). The mutation in these mice has been
mapped to the locus encoding the Six homeobox 2 (Six2) transcription factor. Similar to
the Shroom3 mutant mice, the homozygous mutants are embryonic lethal, but
heterozygotes (Br/+) can live into adulthood although adults show abnormalities
including small kidneys and severe midfacial retrognathia. These mice have
haploinsufficiency of Six2 expression (approximately 50% that of wild-type). In the
kidney, Six2 is normally expressed in the mesenchymal cells. The Br/+ mice with
hypomorphic expression of Six2 have a decreased nephron number similar to our model.
A theory of “nephron endowment” has been developed stating that the number of
nephrons in an individual correlates inversely with the risk of developing hypertension
and chronic renal failure (Brenner et al., 1988; Keller et al., 2003). Br/+ mice have
greater mean arterial pressure indicative of hypertension and deficient GFR. Thus, in the
future, it would be important to see if Shroom3+/Gt mice also experience or are prone to
hypertension as reduced nephron number is associated with an increase in the risk of
hypertension (Fogelgren et al., 2009; Keller et al., 2003; Ruta et al., 2010). This is a clear
experiment for future research on the phenotype of the Shroom3+/Gt mice. Although there
may be a predisposition to kidney disease in Shroom3+/Gt mice since they have a decrease
in nephron endowment, there may need to be addition of a hypertensive insult, such as a
high-salt (5%) diet (Ruta et al., 2010). High-salt diets are increasing in the human
population and it is important to determine those who may be predisposed to
hypertension due to kidney defects. I would hypothesize since the Shroom3+/Gt mice have
a decreased nephron endowment, they will develop greater hypertension as a result of the
high-salt diet than the Shroom3+/+ mice. Hypertension is also a leading factor in the cause
of CKD so it may be a trigger for the Shroom3+/Gt mice to show a more severe kidney
phenotype. Furthermore, it may provide a rationale for analysis of SHROOM3 in human
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patients as part of the diagnosis of hypertension.

4.3 Potential mechanism of loss of Shroom3 action
My results show that one potential cause of the kidney defects present in the Shroom3+/Gt
mice is due to defects in the podocytes. I found that a portion of the podocytes in both
Shroom3+/Gt and Shroom3Gt/Gt do not have the proper apical localization of actin (Figure
19). To determine potential mechanisms for the loss of apical actin, I examined ROCK1
and pMLC distribution in the podocytes as these have been demonstrated to work
downstream of Shroom3 to act on actin (Das et al., 2014; Nishimura & Takeichi, 2008). I
found that some podocytes also lack the apical localization of ROCK1 (Figure 21) and
pMLC (Figure 22). Thus, in the case of podocytes, my results suggest that Shroom3 acts
via its characterized pathway using ROCK and pMLC to change actin organization. The
loss of apical actin can result in disorganization of the actin cytoskeleton and may lead to
podocyte loss.
In order to determine whether there was a significant difference between the podocytes
lacking apical actin, ROCK1 and pMLC, counts were performed. However, significance
was only reached with respect to an increase in the percentage of podocytes lacking
apical actin at 3 months in Shroom3+/Gt (Figure 20) and percent of podocytes lacking
ROCK1 and pMLC in Shroom3Gt/Gt at E13.5 (Figure 23, 24). However, at all time points
there is a trend towards an increase in the percentage of podocytes lacking actin, ROCK1
and pMLC in Shroom3+/Gt and Shroom3Gt/Gt and it appears to be in a dose-dependent
manner. The lack of significance is most likely due to a low sample number for each
group as only 3 embryos per genotype were available at each age. Although, the
differences in the percentage of podocytes that show these localization defects was not
significant in most cases, the very low frequency of the defects in control mice strongly
suggests that if we were able to increase our sample size, we would demonstrate
localization defects at all stages. Thus, my results show that at least part of the problem
with loss of Shroom3 function is at the level of podocytes and disorganization of the actin
cytoskeleton that is vital to podocyte function.
Some of the podocytes seem to be affected by loss of Shroom3, but it is still not
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understood why only certain podocytes show defects. There may be a compensatory
mechanism that is able to save most, but not all podocytes, as there are still apparently
normal podocytes and glomeruli present in all genotypes. It may be that another Shroom
family member has an overlapping expression pattern and function in the kidney and may
be able to compensate for loss of Shroom3, although this does not occur in the neural
tube. All the other members of the Shroom family, Shroom1, Shroom2, and Shroom4, are
expressed in the pronephros of Xenopus (Lee et al., 2009). Thus, although not yet tested,
other Shroom family members may be present in mammalian kidneys and compensate for
loss of Shroom3, although only partially, as defects are still seen.
My results suggest apical localization of ROCK is important for podocyte development
and function. However, the loss of apical ROCK affects a minority of podocytes so it
may be that the loss causes a predisposition to injury rather than demonstrating an
essential ROCK localization. By extension, since ROCK requires RhoA, my results
suggest a beneficial role for RhoA activation in podocytes. This adds further into the
controversy on whether RhoA positively or negatively regulates podocyte function
(Asanuma et al, 2006; Gao et al. 2004; Jeruschke et al., 2013; Kanda et al., 2003; Kikuchi
et al., 2007; Kobayashi et al. 2004; Komers et al., 2011; Liu et al., 2012; Nishikimi et al.,
2004; Peng et al., 2008; Stirzaker et al., 2012; Sun et al., 2006). My results would favour
a role for RhoA in allowing for dynamic activity of the podocytes. However, the premise
that basal levels of RhoA activity are beneficial and increased activity negatively
regulates podocytes is probable (Wang et al., 2012). To verify whether increased levels of
RhoA above basal levels are detrimental would be to overexpress RhoA in these
podocytes and determine if podocyte defects are rescued. Furthermore, inhibition of
ROCK by specific inhibitors such as fasudil and Y27632, can act as a surrogate to
whether RhoA activation is necessary for proper podocyte function by inhibiting
downstream effects of RhoA activity. If the inhibition causes a greater loss of podocytes,
then it suggests that endogenous RhoA is important in podocyte function.
Although only some podocytes do not develop properly, other podocytes may be
predisposed to a disease condition and when injured, those podocytes may show defects
and be lost. For instance, although MYH9 has been associated with CKD by GWAS,
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selective deletion of Myh9 from mouse podocytes resulted in no indication of kidney
disease and what appeared to be a completely normal phenotype (Johnstone et al., 2011).
However, when challenged and predisposed to glomerulopathy via doxorubicin
hydrochloride (Adriamycin), the C57BL/6 mice developed proteinuria and
glomerulopathy. Thus, it may be that partial Shroom3 loss may predispose podocytes to
injury. To test this, I would propose to treat our adult Shroom3 heterozygous mice with
Adriamycin, as done with the Myh9 mice. I hypothesize that the heterozygotes would
show more pronounced kidney disease than control mice.

4.4 Potential podocyte foot process effacement
Some Shroom3+/Gt adult male mice experience proteinuria. Proteinuria is a result of the
loss of filtration barrier integrity of which the podocytes are an important part. My results
suggest a scenario whereby hypomorphic Shroom3 activity results in a loss of actin
localization in podocytes and a disorganization of the actin cytoskeleton. It is known that
when the actin cytoskeleton becomes disorganized, it can result in podocyte foot process
effacement (Faul et al., 2007).
A majority of kidney diseases that progress to CKD begin in the glomerulus. One cell
type within the glomerulus that plays a large role in these glomerular diseases is the
podocyte (Kriz et al., 1998; Pavenstadt et al., 2003). Normally during aging, individuals
lose podocytes, but glomerular disease accelerates this process (Lemley et al., 2002). If
only approximately 60% of podocytes in a particular glomerulus are left, the entire
nephron will be lost. This may explain the loss of glomeruli that I see in Shroom3+/Gt and
Shroom3Gt/Gt mice. Due to rearrangements of the actin cytoskeleton seen in the podocytes
of Shroom3+/Gt adult mice, there may be loss of podocytes and foot process effacement.
One common strategy that podocytes use to deal with stress is to undergo foot process
effacement (Kriz et al., 2013). The signals resulting in foot process effacement are still
not fully understood. Podocyte foot process effacement results in flattening and
broadening of the foot processes, which allows larger macromolecules to be filtered into
the Bowman’s capsule and into the urine resulting in proteinuria. Similar to the zebrafish
model (Yeo et al., 2015), I see greater loss of protein in the urine suggestive of a loss of
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podocyte foot process filtration barrier integrity. Currently our collaborators have
obtained images using scanning electron microscopy (SEM) and transmission electron
microscopy (TEM) that show abnormal spacing of podocyte bodies and short,
disorganized foot processes with reduced interdigitation in Shroom3Gt/Gt mice. Future
work would be to examine the podocytes of Shroom3+/Gt mice to see if similar podocyte
defects are seen.

4.5 Potential consequences of Shroom3 loss on amniotic
fluid composition
Further investigation is needed to elucidate whether kidney defects can, at least in part,
explain the greater amount of amniotic fluid in the Shroom3Gt/Gt compared to Shroom3+/+
and Shroom3+/Gt embryos. It is possible that the exencephaly may be the sole cause for
the increase in amniotic fluid. At least part of the increased fluid content is most likely
due to loss of serum from the skull into the amniotic sac. However, the increase in
amniotic fluid may also be partly attributable to kidney dysfunction and urination by the
embryos.
In order to investigate whether kidney defects contribute to the increased amniotic fluid,
examining kidney specific markers in the amniotic fluid would be important. For
instance, greater presence of podocyte-specific mRNAs, such as podocin or nephrin, in
urine can act as markers of podocyte injury (Sato et al., 2009; Wickman et al., 2013).
Increased amounts of podocyte-specific mRNAs in the amniotic fluid would indicate
kidney defects resulting from loss of podocyte integrity. Furthermore, Shroom3+/+ and
Shroom3+/Gt mice could be compared for differences in amniotic fluid content as my
findings show that Shroom3+/Gt mice show defects similar to the Shroom3Gt/Gt but to some
extent, less severe.

4.6 Mice as a model for CKD
CKD is measured as a chronic irreversible reduction in GFR. Reduced GFR can result
from lower nephron endowment as well as glomerular defects. Humans show a large
variability in the number of nephrons per kidney, ranging from approximately 200,000 to
1,800,000 nephrons per kidney (Hoy et al., 2003; Hughson et al., 2003; Nyengaard &
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Bendtsen, 1992). Mice, on the other hand, have a small variability in nephron number at
approximately 13,000 nephrons per kidney (Rocque & Torban, 2015). Since mice have
lower variability, it is much easier to define a normal range of glomeruli and GFR
compared to humans. Furthermore, metanephric development is the last stage in
mammalian kidney development while the pronephros and mesonephros are transient
structures. This is unlike lower vertebrates such as Xenopus or zebrafish, who have a
functional pronephros and the last stage of development is the mesonephros. Thus, lower
vertebrates are not ideal models because their kidney development does not fully
recapitulate human kidney development.
The general benefit of mouse models is that their genome is easily manipulated, as
demonstrated by the model I used. Furthermore, many mouse strains, including my own,
have the benefit of being inbred. Use of inbred C57BL/6 mice allows for reduced
variability caused by genetic variation (Becker & Hewitson, 2013).
These advantages have led to many mouse models that mimic CKD including both
surgical and genetic models, and specific treatments that induce kidney damage. An
example of a surgical model is unilateral ureteral obstruction involving surgical induction
of infarct by ligation of a renal artery and nephrectomy of varying amounts of the other
kidney tissue (Huang et al., 2013). Unilateral ureteral obstruction recapitulates many key
features of the typical renal fibrogenic response including interstitial capillary
permeability, increase in inflammatory mononuclear cells, and an increase in pro-fibrotic
molecules (Eddy et al., 2012). Genetic models include the knockout of specific podocyte
factors known to induce kidney disease, such as nephrin (Kestilä, 1998) and podocalyxin
(Takeda et al., 2001). Kidney disease can be induced in mice by small molecules that can
induce kidney injury including doses of folic acid that result in interstitial fibrosis.
Another example is deoxycorticosterone acetate in combination with a high salt diet and
unilateral nephrectomy, which induces hypertension with moderate renal injury (Yang et
al., 2010).
Although mice have many advantages, a limitation with the use of C57BL/6 mice, as
used in our study, is that they are generally kidney injury resistant compared to other
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mouse strains (Eddy et al., 2012; Huang et al., 2013). For instance, the unilateral ureteral
obstruction model works in C57BL/6 but the effects are not severe. Unilateral ureteral
obstruction is meant to induce inflammatory tubulointerstitial fibrosis, but only generates
mild scar tissue in C57BL/6 mice (Vielhauer et al., 2001). Also, in protein overload
models such as the albumin overload model, C57BL/6 mice are the least responsive strain
and generally albumin overload induces acute kidney failure rather than chronic kidney
disease (Ishola et al., 2006). Thus, in particular C57BL/6 mice seem to be a very resistant
strain to kidney injury. Thus, I would predict that if we were to backcross our mice into a
strain of mice that was more susceptible to CKD, such as 129/Sv mice, the defects would
be even more pronounced than what I have observed.
Another paper examining the role of Shroom3 in the kidney used a mouse model (Menon
et al., 2015). However the use of the gene trap may be considered more valid because the
other paper used an inducible knockdown of Shroom3 by doxycycline feeding in adult
mice. RTTA elements were linked to the ROSAm26 promoter. The Dox-RTTAresponsive elements were then linked to a Shroom3-specific shRNA to allow Dox feeding
to induce Shroom3 knockdown. Additionally, the article only examined the effects of
Shroom3 knockdown on the tubules. The gene trap model on the other hand causes nonfunctional Shroom3 from the beginning of development, which would be predicted to
more accurately represent SHROOM3 hypomorphs as SHROOM3 function would be
decreased from the onset of birth. Additionally, Shroom3 is found in other cell types
other than just the tubules (Figure 9, 10, 11, 12, 13, 14, 15) so my research predicts that
the podocytes are an important target of Shroom3 activity. Therefore, my use of C57BL/6
mice with loss of Shroom3 is a good model to examine the genetic role of Shroom3 in
kidney development and function.

4.7 Conditional knockout of Shroom3
Important future studies that should follow my initial work would be to develop a
Shroom3 conditional knockout mouse model. This would allow homozygous mice for
loss of Shroom3, in specific tissues, to potentially survive into adulthood and thus they
can be studied without the exencephaly. Also, conditional knockout mice will be
important in order to verify which cell types account for specific defects. For example,
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Shroom3 is expressed in the cap mesenchyme, collecting ducts, ureter, tubules and
podocytes. It will be important to examine a conditional knockout in kidney podocytes.
However, also of interest is the cap mesenchyme in embryonic development. The cap
mesenchyme is interesting as Shroom3 is typically found and is known to cause tissue
morphogenesis in epithelial tissues. However, the cap mesenchyme is, as expected from
its name, mesenchymal. Thus, it would be interesting to see what role Shroom3 plays in
non-epithelial tissues and whether it is essential for the mesenchymal to epithelial
transition in these progenitors.
Currently our lab is developing a conditional mouse model that will allow for cell-type
specific knockouts using a Cre driver as the exon 4 of Shroom3 will be flanked by loxP
sites. Cre recombinase is an enzyme that can be generated in a specific cell type by
inserting the gene encoding it under the control of a tissue specific promoter, usually as a
transgene. Expression of the Cre recombinase results in the excision of DNA that is
located between two loxP sites.
The loxP sites for our Shroom3 vector are around exon 4. This would cause removal of
exon 4 of Shroom3 and this will disrupt the reading frame and cause a presumably nonfunctional protein. Future work on determining the role of Shroom3 in specific cell types
in the kidney would use a podocyte specific Cre-line such as a Podocin-Cre (Blattner et
al., 2013; Brähler et al., 2012; Chase et al., 2012 Moeller et al., 2003). Podocin is specific
to the slit diaphragm that is the protein network between neighbouring podocytes. It
would then be possible to examine the role of Shroom3 within the podocytes without the
loss of Shroom3 in the neural tube and other organs. With a podocyte-specific Cre, it will
be able to definitively demonstrate whether the glomerular defects and decreased nephron
number is caused by defects in the podocytes. The role of Shroom3 in glomerular and
podocyte loss is still not fully clear because glomerular cysts can also be caused by tubule
defects (Rocque et al., 2015) and there is relatively strong Shroom3 expression in the
tubules at least in adults.
Other specific Cre drivers could be used to determine what defects are associated with
knockout of Shroom3 in other kidney cell types. For a Cre driver in the cap mesenchyme,
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examples of genes include Tcf21/Pod1-Cre that would express Cre in the cap
mesenchyme and subsequent nephron progenitors (Maezawa et al., 2012), or Sall1-Cre
that is specific, in the kidney, to the cap mesenchyme (Inoue et al., 2010). However, the
Sall1-Cre has the disadvantage of Sall1 expression in other cell types and thus would
cause loss of Shroom3 in other organ systems.
To test for a role for Shroom3 in the collecting ducts, an Aquaporin 2-Cre (Raphael et al.,
2007) or Hoxb7-Cre (Rubera et al., 2003) could be used as these would result in loss of
Shroom3 in both the collecting ducts and ureter. Previous work done in the lab identified
a rare example of hydronephrosis in an 8-month old Shroom3+/Gt male. Hydronephrosis is
dilation of the collecting duct and pelvis of the kidney that can result from obstruction or
functional impairment of the smooth muscle layer of the ureter (Chevalier et al., 2010).
To test the role of Shroom3 in formation or function of the ureter, a Tbx18-Cre (Trowe et
al., 2012) could be used. Thus, use of a conditional Shroom3 knockout model could
provide important information on the role of Shroom3 in different cell types within the
kidney.

4.8 Potential role for Shroom3 in the PCP pathway in
podocytes
PCP is required for polarization of cells and is essential in the organization of epithelial
structures (Gubb & García-Bellido, 1982; Wong & Adler, 1993). PCP is non-canonical
Wnt signaling, meaning that it is independent of β-catenin. PCP controls the axis of
polarity perpendicular to apicobasal polarity (Wallingford, 2012). This is similar to how
the foot processes of podocytes are arranged along the glomerular capillary and GBM,
which is in a perpendicular manner to their apicobasal polarity (Rocque et al., 2015).
Some core PCP proteins, including Vangl1, Vangl2, and Dvl2 were detected in glomeruli
both in vivo and in vitro. Furthermore, in embryonic mouse samples, Vangl2 was
detected more specifically in the basolateral aspects of podocytes at early and late
capillary stages (Babayeva et al., 2010). Not only do these core PCP proteins appear to be
present, but they also seem to activate the PCP pathway in podocytes as in vitro human
and mouse podocytes had a robust increase in the number of actin stress fibres with
Wnt5a activation. Wnt5a is a known activator of non-canonical Wnt signaling that drives
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PCP signaling. PCP activation by Wnt5a results in Dvl2 phosphorylation and localization
to the plasma membrane and activation of Dishevelled associated activator of
morphogenesis 1 protein (Daam1). Both Dvl2 and Daam1 are downstream effectors of
PCP. There is also a redistribution of nephrin, a podocyte-specific protein, from the slit
diaphragm to internal cell compartments. These Wnt5a stimulated podocytes show
greater migrational activity in vitro. Vangl2 short hairpin RNA (shRNA) causes rounding
of podocytes and fewer cellular projections with reduced actin stress fibres in vitro.
Furthermore, Vangl2 directly interacts with the slit-diaphragm protein Membraneassociated guanylate kinase inverted 2 (Magi-2) and interacts with nephrin. Thus, the
PCP pathway is important in podocyte function and actin stress fibre formation.
An important protein in the PCP pathway is Vangl2. Loop-tail (Lp) mice contain a
mutation in Vangl2 (Kibar et al., 2001; Murdoch et al., 2001). Homozygous Lp mice die
in utero due to a completely open neural tube in the hindbrain and spinal region (similar
to craniorachischisis in humans). Heterozygous Lp mice have a characteristic looped-tail
phenotype. This phenotype is also similar to what I see and has been reported
(Hildebrand & Soriano, 1999) with the Shroom3 gene trap suggesting a similar pathway.
Homozygotes for the gene trap have 100% penetrant exencephaly and some of the
heterozygotes for the gene trap have a kinked or curly tail. There is already evidence that
Shroom3 is involved in the PCP pathway in the neural tube (McGreevy et al., 2015) as
evidenced by the open neural tube and curly tails, but there may also potentially be a
connection in the kidney and more specifically, the podocytes.
Vangl2 expression is highly dynamic whereby it is highly expressed in embryonic
development, but significantly diminished, at least at the protein level, in adult kidneys
(Babayeva et al., 2010; Rocque et al., 2015). As Vangl2 depleted kidneys also show
tubular defects, deletion of Vangl2 specifically in podocytes can circumvent the tubular
deficits. Deletion of Vangl2 specifically in the podocytes results in a greater number of
immature glomeruli, smaller glomerular size and reduced number of podocytes per
glomerulus compared to controls (Rocque et al., 2015). In adult mice, when the kidneys
are fully mature, the Vangl2 depleted podocytes caught up to their wild-type counterparts
only in the maturity of the glomeruli. However, deletion of Vangl2 did not affect the
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filtration barrier function of the podocytes in the adult mice at 1 year. Although these
Vangl2 podocyte deletion mice appeared to be normal, when challenged with glomerular
injury, they show increased urinary albumin and glomerulosclerosis. Thus, Vangl2 seems
to be important in podocyte differentiation and glomerular maturation and to some degree
dispensable at later ages unless injured.
Further research will elucidate whether Shroom3 is downstream of the PCP pathway in
podocytes. The mice harbouring Vangl2 deletion specifically in the podocytes seem to
have a similar phenotype to my Shroom3+/Gt mice as there are many glomerular defects
and more specifically podocyte defects. Because there is a similar phenotype, it suggests
that Vangl2, and in general PCP, may be part of the same pathway as Shroom3.
Furthermore, generally different proteins of the PCP pathway act either basolaterally or
apically so it would be interesting to see if Shroom3, an apical acting protein, and
Vangl2, a basolaterally located protein in podocytes, may act on opposing sides to drive
PCP.

4.9 Translation to the human condition
PolyPhen-2 predicts that there are human variants of SHROOM3 that cause detriment to
SHROOM3 function. I assume that these individuals do not have complete loss of
SHROOM3 function as these individuals would not be expected to survive into
adulthood. Thus, I would predict that these individuals have hypomorphic SHROOM3
activity, similar to what I observe in the Shroom3+/Gt mice. It would be interesting to
determine whether these hypomorphs show some of the disease pathologies that I see in
the Shroom3+/Gt mice such as glomerular cysts and decreased nephron endowment.
There are several lines of evidence suggesting that different alleles of SHROOM3 may be
deleterious. First, there are humans that have predicted deleterious alleles of SHROOM3,
based on the correlation of SHROOM3 mutations with heterotaxy (Tariq et al., 2011).
Although the evidence for the link to heterotaxy is strong, it is strictly correlative.
Secondly, PolyPhen-2 analysis, where known human mutations are analyzed for likely
impact on protein structure and functions, has identified many mutations in human
SHROOM3 that would be predicted to impair its activity (Table 1). Importantly, many of
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these changes occur in the three conserved domains within the protein. Third, the SNP
that was identified to correlate with CKD is intronic. Nevertheless, recent studies suggest
that presence of that SNP in donor allografts results in decreased eGFR and increased
allograft dysfunction at 12 months (Menon et al., 2015). Taken together, this strongly
suggests that hypomorphic SHROOM3 activity is likely in some humans.
Another interesting finding from the PolyPhen-2 predictions is that many SNPs in the
PDZ domain were predicted to be probably damaging. Currently, it is not known what
role the PDZ domain plays in Shroom3 function and is thought to be dispensable to
Shroom3’s ability to drive apical constriction (Hildebrand & Soriano, 1999). However,
PDZ domains are one of the most common mediators of protein-protein interactions in
mammalian cells (Chi et al., 2012). Many proteins that contain PDZ domains are
involved in scaffolding, trafficking and signaling. Therefore, since PolyPhen-2 predicts
many SNPs within the PDZ domain to be deleterious to protein function, it suggests that
the PDZ domain of Shroom3 has a function that has yet to be elucidated and should be an
area of future research.
My work could be translatable to humans as it suggests potential defects in individuals
who have decreased SHROOM3 function and predicts that these individuals may be
predisposed to CKD as they have decreased glomerular number and podocyte defects.
Early diagnosis and treatment of these hypomorphs could be important in predicting and
slowing progression of CKD and therapies can be created that potentially target
improving SHROOM3 function or downstream effectors of SHROOM3.

4.10 Conclusions
CKD is caused by a gradual loss in kidney function as evidenced by reduction in GFR to
less than 60 mL/min/1.73m2. There is a definite genetic component to kidney function
that can cause, or predispose an individual to, kidney disease. Potential early diagnosis of
genetic risk factors for CKD could help identify individuals at risk and provide rationale
for treatments to either slow or prevent progression of loss of kidney function based on
knowledge of SHROOM3 activity. SHROOM3 has recently been listed in a number of
GWAS to have a potential link to CKD. Because these studies are simply correlational
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and do not prove causation, my experiments provide important verification that
SHROOM3 is important in the kidney.
When I initiated these studies, I proposed to use a mammalian mouse model known to
have loss of Shroom3 function to investigate where and when Shroom3 is expressed and
examine how Shroom3 may alter kidney function. I demonstrated Shroom3 expression in
the podocyte, a specialized visceral epithelial cell surrounding the capillaries of the
glomerulus. The podocytes are an integral part of the glomerular filtration barrier and
often defects in podocytes are seen in CKD. I show that there are glomerular defects in
mice both heterozygous and homozygous for the loss of Shroom3 and that these defects
may be related to the loss of known Shroom3 activities in the podocyte. It is important to
note that not all podocytes are affected. Some podocytes seem to have mislocalization of
actin to the apical surface as a result of loss of ROCK1 and pMLC localization to the
apical surface. This could explain my observed loss in nephron number resulting in
reduced nephron endowment without total loss of podocytes. I also see proteinuria in
some Shroom3+/Gt adult 1-year-old males, which could be explained by the podocyte
defects seen. Therefore, Shroom3 is important in the development and maintenance of
podocyte function.
Therefore, my results have verified that there is a role for Shroom3 in the kidney in both
its development and adult function. Thus, Shroom3 is an important component of kidney
health and even partial loss of its activity may result in CKD.
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Appendices
Glomerular)death)between)E13.5)to)
E15.5)
Shroom3+/+)
+/+)

Shroom3+/Gt)
+/7)

Shroom3Gt/Gt)
7/7)

Figure A1. E13.5 Shroom3+/Gt and Shroom3Gt/Gt kidneys show
collapsing/degenerating glomeruli. H&EE13.5)
staining of E13.5 kidneys shows normal
glomerular development in Shroom3+/+ kidneys while Shroom3+/Gt and Shroom3Gt/Gt
kidneys show glomeruli that are collapsing/degenerating (black arrows). These
collapsing/degenerating glomeruli are seen as dark circles in the histology. This image
was provided courtesy of my collaborators, Hadiseh Khalili and Dr. Darren Bridgewater.
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